Evaluation of resolvin E1 as a potential therapeutic for rheumatoid arthritis by Miyashiro, Joy
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2014
Evaluation of resolvin E1 as a
potential therapeutic for
rheumatoid arthritis
https://hdl.handle.net/2144/14644
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
Thesis 
 
 
 
 
EVALUATION OF RESOLVIN E1 AS A POTENTIAL  
THERAPEUTIC FOR RHEUMATOID ARTHRITIS 
 
 
 
by 
 
 
 
 
JOY SACHIE MIYASHIRO 
 
B.S., Massachusetts Institute of Technology, 1994 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Arts 
 
2014  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014 
 JOY SACHIE MIYASHIRO 
 All rights reserved  
   
Approved by 
 
 
 
 
 
First Reader _________________________________________________________ 
 Tsuneya Ikezu, M.D., Ph.D. 
Professor of Pharmacology and Experimental Therapeutics, and 
Neurology 
 
Second Reader _________________________________________________________ 
 Marion Kasaian, Ph.D. 
Adjunct Professor of Pharmacology and Experimental Therapeutics 
 Research Fellow, Pfizer, Cambridge, MA 
 
 
 
 
 
 iv 
 
DEDICATION 
 
 
This work is dedicated to Daniel Beane and Hailey Beane who are the inspiration for this 
and all my journeys. 
 
 
  
 v 
 
ACKNOWLEDGMENTS 
 
I am grateful to have participated in classes, seminars and research through the 
Boston University Department of Pharmacology and Experimental Therapeutics – Pfizer 
graduate training program.  I would like to thank my fellow students in this program, 
Elizabeth Kieras, Nicole Piche-Nicholas, and Paul Wu for scientific discussion, advice 
and support. I would also like to acknowledge the scientific guidance I received from my 
Pfizer mentors, John Douhan, III, Ph.D., Suzana Marusic, M.D., Ph.D. and Deborah 
Young, Ph.D. I also gratefully acknowledge the many efforts of Cara Williams, Ph.D. 
and David Farb, Ph.D. in coordinating the BU-Pfizer graduate training program. 
I would like to acknowledge the support and scientific critique of my first reader, 
Tsuneya Ikezu, M.D., Ph.D., and my second reader, Marion Kasaian, Ph.D.  I would also 
like to thank and acknowledge Carol Walsh, Ph.D. for her continual support, guidance 
and encouragement through my graduate career.  I am grateful to faculty, students and 
staff of the Department of Pharmacology for their commitment to an exciting 
environment for scientific learning. 
 
  
 vi 
 
EVALUATION OF RESOLVIN E1 AS A POTENTIAL THERAPEUTIC FOR 
RHEUMATOID ARTHRITIS 
JOY SACHIE MIYASHIRO 
ABSTRACT 
 Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic 
inflammation, pain and joint remodeling.  Existing RA therapies such analgesics and anti-
inflammatories can treat symptoms.  More recent strides in disease modifying anti-
rheumatic drugs (DMARDs) can slow progression of disease.  However, there is still no 
therapeutic that can reverse disease damage and there is no cure for RA. Resolvin E1 
(RvE1) is an endogenous lipid initially identified as a key pro-resolving mediator.  By 
tamping down expression of pro-inflammatory cytokines, tumor necrosis factor- (TNF-
 and interleukin-1 (IL-1, RvE1 is able to down-modulate inflammation and return 
an inflamed tissue to a homeostatic state.  More recently, RvE1 has been shown to act 
directly to inhibit inflammatory pain through central and peripheral nervous system 
mechanisms.  RvE1 has also been shown to restore bone homeostasis by balancing 
osteoclast and osteoblast activity. In contrast to current therapeutics that treat symptoms 
and slow disease progression, a RvE1 pathway agonist has the potential to reverse RA by 
resolving inflammation, reversing bone remodeling and returning joints to normal 
homeostasis. 
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INTRODUCTION 
Rheumatoid Arthritis (RA) 
Epidemiology of RA 
Rheumatoid Arthritis (RA) is a chronic polyarthritic autoimmune disease 
characterized by swelling in at least five joints, debilitating pain, and ultimately joint 
remodeling (Silman AJ, et al. 2001).  It is estimated that between 2001 and 2005, 
approximately 0.5-1% of adults worldwide and 0.6% of the adults in the United States 
suffered from RA (Sacks JJ, et al. 2005). As with many autoimmune diseases, RA is 
about three times more likely in females than in males.  RA is more prevalent among 
adults over 60 years old (Silman AJ, et al. 2001).   
 
Etiology of RA 
The cause of RA is unknown, but is believed to be a combination of genetic 
factors, such as HLA class II gentoype (Scott DL, et al. 2010), and environmental 
exposures, such as smoking, dietary factors and infections (Silman AJ, et al. 2001). 
Research into the molecular mechanisms of RA is focused on three main areas: 
inflammation, pain, and joint remodeling. 
 
Treatments for Rheumatoid Arthritis 
 Early pharmacological intervention for RA focused on treating the symptoms of 
disease.  Analgesics, from acetaminophen to narcotics, are used to treat RA pain as it 
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escalates through disease progression (TABLE 1).  Inflammation can be controlled to 
some degree with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or 
celecoxib for chronic use or steroids, such as prednisone, for acute episode short-term use 
(TABLE 1).  While these therapies have some efficacy at treating RA symptoms, 
underlying causes of the disease remained and thus joint destruction continued. 
Disease-modifying anti-rheumatics (DMARDs) changed the rheumatoid arthritis 
treatment landscape (TABLE 1).  Patients now had a therapeutic regime that could stop 
the RA symptoms of pain and inflammation and also slow disease progression.   
Introduced to RA in the 1970’s and popularized in the 1980’s, one of the most 
notable early DMARD, the orally-administered small molecule drug, methotrexate, is 
now considered the “anchor” of RA treatment (Pincus T, et al. 2003). Methotrexate was 
initially used as an anti-cancer therapeutic. Although the mechanism of action as an RA 
therapeutic is unclear, methotrexate is known to inhibit dihydrofolate reductase, an 
essential enzyme in DNA synthesis and cell proliferation (Cronstein BN, et al. 2005). 
The major routes of methotrexate resistance include rapid metabolism of methotrexate to 
the partially inactive 7-hydroxymethotrexate, defective transport due to reduction in 
expression or activity of reduced folate carrier (RFC), or increased methotrexate efflux 
via ATP-binding cassette (ABC) subfamily (van der Heijden JW, et al. 2007).  
Gastrointestinal adverse effects are the most common complaints and are reported by as 
many as 66% of RA patients on methotrexate therapy (Verstappen SM, et al. 2010).  
Approximately 12% of RA patients discontinue methotrexate use due to adverse effects 
or ineffectiveness within the first two years of treatment (Verstappen SM, et al. 2010). 
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However, methotrexate is the standard of care in RA because it is effective, it can be 
taken orally, and it is inexpensive (TABLE 1). 
In the 1990s, the quality of life expectation of RA patients was dramatically 
increased with the advent of biological therapies.  Monoclonal antibodies against tumor 
necrosis factor- (TNF-, infliximab (Remicade®) and adalimumab (Humira®), and a 
soluble TNF- receptor Fc fusion protein, etanercept (Enbrel®), work by neutralizing 
TNF-.  These treatments, either alone or in combination with methotrexate, have 
become the new gold standard in RA treatment.  Other biologic DMARDs can also be 
used to treat RA if TNF- blockade fails.  Kineret®, a recombinant non-glycosylated IL-
1 receptor agonist, (Brensihan B, et al. 2003; Jiang Y, et al. 2000) or Rituxan, a B-cell 
depleting anti-CD20 anitbody (Roll P, et al. 2008) are among a growing field of immune-
modulating biologics in the RA treatment arsenal.  Many patients see dramatic 
improvement in flexibility and dramatic decrease in pain with biologics over 
methotrexate (TABLE 1). 
Biologics are protein therapeutics, such as antibodies, receptor-Fc fusions, and as 
a class present many challenges.  Biologics can themselves be immunogenic, and 
therefore a patient’s immune system can mount an anti-drug antibody (ADA) response, 
which can render the drug inactive.  About 9% of patients are primary non-responders.  It 
is estimated that about 30% of patients discontinue anti-TNF therapy due to 
ineffectiveness within the first year of treatment (Calabrese LH. 2003).    Possible 
mechanisms of non-response to TNF- inhibitor therapy include existing anti-TNF 
antibody titers and increased anti-TNF- titers over time (Calabrese LH. 2003).  
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Compared to methotrexate-treated patients, patients who take the anti-TNF therapies 
adalimumab, etanercept and infliximab, were observed to have higher rates of skin 
infection, pneumonia, cystitis, and tuberculosis (TB) (TABLE 1).  Staphylococcus 
aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa and 
Salmonella emerged as frequently observed bacterial pathogens. Varicella zoster virus 
and Herpes simplex virus caused most cases of viral infections. Mucocutaneous 
candidiasis accounted for most fungal infections (Pérez-Sola MJ, et al. 2011). 
Tuberculosis infection or reemergence is a risk factor for patients on anti-TNF- 
therapies. RA patients who have been treated with biologics have a four-fold increased 
risk of TB over the general population (Arkema EV, et al. 2014).  However, when 
patients are treated with latent TB infection (LTBI) standard of care, there is no 
statistically significantly increased risk of active TB in LTBI-positive TNF- inhibitor 
patients compared with LTBI-negative TNF- inhibitor patients (Kwon M, et al. 2014). 
As a class, biologics are extremely expensive and must be injected either 
subcutaneously or intravenously, disqualifying them as first-line therapies.  However, 
patients demand these therapeutics because they are clinically efficacious. 
The newest addition to the RA therapeutic arsenal is Xeljanz®, a Janus kinase 
(Jak) antagonist small molecule drug (TABLE 1).  The Jak-Stat signaling pathway 
transmits signals from cytokine receptors that employ the c chain; these include IL-2R, 
IL-4R, IL-7R, IL-9R, IL-15R, and IL-21R.  It is thought that by inhibiting Jak-3-
mediated cytokine receptor signal transduction, Xeljanz® dampens autoimmune response 
in RA (Maeshima K, et al. 2012; Zerbini CAF and Lomonte ABV. 2012).  Xeljanz® also 
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inhibits Jak-1, and carries a black box warning about the increased risk of serious 
infection, cancers and lymphoma (Pfizer, 2012). 
Xeljanz® and biologic TNF- antagonist therapeutics are more targeted to the 
immune system than methotrexate. However, even these more immune system-targeted 
drugs only inhibit on-going inflammatory damage without enhancing resolution; and 
therefore do not cure arthritis.   
The lifestyle enhancing activity of DMARDs has set the bar high for the next 
generation of RA therapy.  Treatment of symptoms and even slowing of disease 
progression will not be enough.  Current treatments address pain and inflammation, but 
do not address bone loss or joint remodeling. The next leap in RA therapy must be a drug 
that can resolve inflammation and reverse joint damage. 
Mechanisms of RA 
In order to design better therapies to treat RA, it is necessary to understand the 
cellular and molecular mechanisms that underlie disease progression and symptoms.  
Research into the molecular mechanisms of RA is focused on three main areas: 
inflammation, pain, and joint remodeling. 
  Inflammation 
 
During normal inflammation, the immune system directs a protective program at 
the sight of infection or injury by recruiting neutrophil and macrophages, increasing 
inflammatory cytokines, and clearing debris, such as dead cells or invading pathogens. 
When carried out successfully, the inflammatory program is transient and gives way to a 
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resolution program, catabasis, which promotes healing and return to homeostasis.  
Catabasis is an active resolution of inflammation distinct from merely anti-inflammatory 
action (Serhan CN, et al. 2007). However in autoimmunity, the adaptive immune system 
chronically remains in the inflammatory state, autoreactive activated T cells continuously 
to secrete pro-inflammatory cytokines and activated B cells produce autoreactive 
antibodies which damages affected tissues over time.   
 In the early stages of RA, dendritic cells, producing the cytokines TNF- and 
interleukin-12 (IL-12), activate naïve T lymphocytes to differentiate into pro-
inflammatory mature T-lymphocytes:  IFN--producing TH1 lymphocytes or interleukin-
17-producing TH17 lymphocytes (Silverman GJ and Carson DA. 2003).  In response, 
infiltrating macrophages produced the inflammatory cytokines TNF- interleukin-1 
(IL-1, and interleukin-6 (IL-6) (Figure 1A) (Choy E. 2012). 
As disease progresses, activated B lymphocytes can up regulate co-stimulatory 
molecules to further T lymphocyte activation (Figure 1B) (Choy E. 2012).  In human RA, 
there are three recognized autoantibodies: anti-rheumatoid factor (anti-RF), anti-
citrullinated peptides (anti-CCP), and anti-type II collagen (anti-CII) (Silverman GJ and 
Carson DA. 2003). While all three are biomarkers for cartilage erosive arthritis, only anti-
CII has been directly linked to RA pathogenesis via animal models (Rowley MJ, et al. 
2008). Citrullination is a post-translational modification that converts the amino acid 
arginine to the non-standard amino acid citrulline via peptidylarginine deiminase (PAD)-
catalyzed replacement of the aldimine with a ketone.  Anti-citrullinated protein antibodies 
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form immune complexes and can drive complement cascade (Choy E. 2012). Fibrin and 
fibrinogen in the arthritic joint may be the source of citrullinated proteins in RA.  
In addition to B cells, other immune cells also participate in RA pathogenesis.  
Activated T cells recruit innate immune cells such as macrophages and neutrophils into 
the synovial space between joints.  TNF-, IL-6 and IL-1 are usually produced by 
macrophages in the acute phase response, but remain up regulated in RA (Figure 1A) 
(Choy E. 2012).  TNF- is a pyrogen, can up-regulate macrophage phagocytic activity, 
can up regulate nuclear factor kappa-light-chain-enhancer of activated B cells (NFB) 
transcription factor expression, and is a potent chemoattractant for neutrophils (Old LJ. 
1985).   Signaling through the TNF- and IL-1 pathways has been shown to up regulate 
cyclooxygenase-2 (COX-2), an enzyme that can convert arachidonic acid (AA) to 
prostaglandin H2 (PGH2), an inflammatory mediator. 
Rheumatoid arthritis patients have a two-fold higher risk of developing 
cardiovascular (CV) disease, even after traditional CV risk factors, such sedentary 
lifestyle and high cholesterol, have been taken into account (Sattar N, et al. 2003). 
Indeed, while RA patients do not have increased hypertension or diabetes mellitus, 
traditional CV risk factors (Boyer JF, et al. 2011; del Ricon ID, et al. 2001), these 
patients have a higher incidence of atherosclerosis and increased mortality due to CV 
disease (Gonzalez-Juanatey C, et al. 2003; Nurmohamed MT. 2009). Atherosclerosis has 
some features of autoimmune disease, in particular, activated T and B cells in the 
vasculature.  It is hypothesized that in RA, clonally expanded activated T produce high 
levels of TNF-, endothelin and collagenases injure vasculature, thus contributing to 
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atherosclerosis (Hollan I, et al. 2013). Therefore, the chronic inflammation in RA is a 
mechanism, not just for joint damage but may contribute to damage to other organs as 
well. 
  Pain 
 
 Pain is the most common symptom that drives an RA patient to initially seek out 
medical attention and continues to be a major patient complaint throughout disease 
progression. Molecular mechanisms of RA pain are associated with both inflammatory 
mediators and neuropeptide mediators. 
 The inflammatory pain associate with RA is mediated by peripheral and central 
mechanisms. After tissue injury, inflammatory mediators (TNF-, IL-1 and pro-
inflammatory prostaglandins) can induce peripheral sensitization, sensitization of 
nociceptor terminal in inflamed tissue and in nociceptor cell bodies in the dorsal root 
ganglion (DRG) (Cheng JK and Ji RR. 2008).  TNF-, IL-1 and prostaglandins 
produced in the spinal cord rapidly induce inflammatory pain via central sensitization in 
spinal cord dorsal horn neurons (Hess A, et al. 2008; Kawasaki Y, et al. 2008; Samad 
TA, et al. 2001). 
 Two neuropeptides, substance P (SP) and calcitonin gene related peptide (CGRP) 
are found in high abundance in RA patient synovial fluid as compared to normal controls 
(Black PH. 2002).  SP and CGRP can act on transient receptor potential cation channel, 
subfamily V, member 1 (TRPV1) or capsaicin (CAP) receptors expressed locally on 
synoviocytes and centrally on the dorsal root ganglion neurons to promote a pain 
response (Geppetti P, et al. 2008; Lin Q, et al. 2007). 
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  Bone damage 
 
 In healthy bone, there is a homeostatic balance between bone formation and bone 
resorption.  In RA tissue, this balance is skewed toward bone resorption on both sides of 
the bone homeostasis equation; osteogenesis and osteolysis.  Evidence suggests that this 
imbalance is tightly linked to the autoimmune state, and that infiltrating activated 
immune cells such as macrophages, dendritic cells, B cells, T cells, and mast cells 
directly and indirectly contribute to bone erosion (Figure 2) (Choy E, 2012). 
On the one side of the bone homeostasis equation, bone resorption is favored by 
inflammatory cytokines and recruitment of monocytes in the inflamed RA joint. 
Increased macrophage colony-stimulating factor (M-CSF) and receptor-antagonist of NF-
B ligand (RANKL), up regulated in RA synovial tissue, signal precursor macrophages 
to differentiate into bone-resorbing osteoclasts (Gravallese EM, et al. 2000).  In addition, 
inflammatory cytokines such as TNF-, IL-1, IL-6 and IL-17 further drive osteoclasts 
to maturity (Lam J, et al. 2000; Lubberts E, et al. 2003; Sato K, et al. 2006; Wei S, et al. 
2005). 
On the other side of the bone homeostasis equation, bone formation is impeded in 
the inflamed RA joint.  TNF- induces Dickkopf-1 (DKK-1) proteins, which interfere 
with signaling through Wingless-type MMTV integration site family (Wnt) proteins. 
Interference with Wnt signaling prevents mescenchymal cell differentiation into 
osteoblast, the bone forming cells (Diarra D, et al. 2007). DKK-1expression in RA 
patient serum was significantly higher than in healthy controls.  DKK-1 expression 
significantly decreased in RA patients treated with anti-TNF- therapies, such as anti-
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TNF- antibodies, or recombinant TNF- receptor-Fc chimeric proteins.  DKK-1 levels 
in patient serum correlated with bone erosion as measured by Sharp radiologic change, 
and with other biomarkers of inflammation such as serum C-reactive protein (CRP) 
levels, and erythrocyte sedimentation rates (ESR) (Diarra D, et al. 2007).   
Taken together, chronic inflammation in the RA joint results in increased 
osteoclast bone resorption and decreased osteoblast bone formation, which leads to joint 
remodeling through net bone loss.  
 
Cyclooxygenase-2 (COX-2) 
The cyclooxygenase (COX) pathway is important in both inflammation and in 
resolution of inflammation (Figure 3) (Serhan CN and Petasis NA. 2011). There are three 
major isozymes, COX-1, COX-2, and COX-3.  COX-1 is constitutively expressed in 
most mammalian tissues.  COX-2 expression is induced in activated macrophages, 
inflamed tissue, and some carcinomas. COX-3, also called COX-1b or COX-1v, is a 
splice variant of COX-1, which retains intron 1 and has a frame shift mutation rendering 
it non-functional in humans.  COX-1 and COX-2 can convert the polyunsaturated fatty 
acids (PUFA), arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) into potent pro-inflammatory or anti-inflammatory mediators (Serhan CN 
and Petasis NA. 2011). 
COX-1 and COX-2 convert arachidonic acid, and6 PUFA, into prostaglandin 
H2 (PGH2). PGH2 is then further converted to other pro-inflammatory mediators.  PGE 
synthase converts PGH2 into PGE2, which can signal through its receptors to mediate 
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pain, fever and vasodilation. Homeostasis of blood clot formation is regulated by 
prostacyclin (prostaglandin I2, PGI2) and thromboxane 2 (TXA2), products of PGH2 
conversion by prostacyclin synthase and thromboxane synthase, respectively.  PGI2 
inhibits platelet aggregation and is an effective vasodilator.  In contrast, TXA2 promotes 
platelet aggregation and is a potent vasoconstrictor.  These products are lipid mediators 
that help direct inflammatory cell and molecular programs. 
Paradoxically, COX-2 can also catalyze the production of lipid mediators that 
help direct pro-resolution cell and molecular programs. Pro-resolving lipid mediators 
include arachidonic acid-derived lipoxins, ω3-eicosapentaenoic acid-derived resolvins of 
the E-series, docosahexaenoic acid-derived resolvins of the D-series, protectins and 
maresins (Serhan CN and Chiang N. 2007).   
Aspirin, one of the first NSAIDs, irreversibly acetylates serine in the active site of 
the cyclooxygenase enzymes, COX-1 and COX-2.  Previously, it was thought aspirin’s 
only pharmacological activity was as a COX enzyme antagonist, inhibiting the 
production of pro-inflammatory lipid mediators.  However, now it is understood that 
aspirin’s acetylation of COX enzymes also confers a new enzymatic activity resulting in 
the production of aspirin-triggered pro-resolving lipid mediators (Serhan CN and Chiang 
N. 2007).  Currently, aspirin is the only NSAID that has shown this second, pro-resolving 
activity.  In the context of RA, this suggests that non-aspirin NSAIDs may inhibit 
inflammation in the short-term, but may also block resolution of inflammation. 
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Resolvin E1 (RvE1) 
Resolvins, lipoxins and protectins have anti-inflammatory and pro-resolving 
activities. (Table 2) (Serhan CN, et al. 2008).  Resolvins have also been reported to have 
analgesic properties that are both anti-nociceptive and anti-inflammatory (Table 3) (Ji 
RR, et al. 2011).  RvE1 also has activity in bone damage healing (Gao L, et al. 2013; 
Hasturk H, et al. 2007). Thus, only RvE1 has the potential to treat RA in all three 
mechanisms of disease: inflammation, pain and bone destruction. 
 
  RvE1 Endogenous Synthesis 
 
 RvE1 is an ω3-eicosapentaenoic acid (EPA)-derived resolvin of the E-series, 
synthesized through an orchestrated cooperation between vascular endothelial cells and 
activated leukocytes.  During inflammation and in the presence of aspirin, vascular 
endothelial cells convert EPA to 18R-hydroxyeicosapentaenoic acid (18R-HEPE) and 
release it into the extracellular space.  Proximal polymorphonuclear leukocytes (PMNs) 
further take up the 18R-HEPE further transform it into RvE1.  Alternatively, RvE1 can 
also be produced through aspirin-independent cytochrome P450-mediated mechanisms
 
(Node K, et al. 1999). 
 
  RvE1 and ChemR23 
 
Chemerin receptor 23 (ChemR23) is a G-protein coupled receptor that binds both 
the peptide Chemerin and the lipid mediator RvE1.  It was first identified as the receptor 
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of RvE1 through a functional screen of LTB4 receptor-related G-protein coupled 
receptors (GPCRs) transfected into HEK cells.  RvE1 inhibits TNF--induced NF-B 
activation in a concentration-dependent manner with an EC50 of 1.0 nM in ChemR23-
transfected, but not in mock-transfected HEK cells (Figure 4) (Arita M, et al. 2005).  
3
H-
RvE1 bound to ChemR23-transfected HEK with a high affinity (Kd of 11.3 nM) (Arita 
M, et al. 2005).     
Prochemerin, a 163-amino acid protein is processed to a 143-amino acid mature 
secreted chemerin protein via removal of the 20-amino acid signal sequence (Figure 5) 
(Du XY and Leung LL. 2009).  Sequential proteolytic cleavage of chemerin results in 
chemotaxis of activated macrophages and pro-inflammatory activity (Table 4) (Du XY 
and Leung LL. 2009). Further processing produces to N-terminally truncated 
polypeptides: chemerin 
151–157
, chemerin 
149–157
, chemerin 
148–157
, and chemerin 
146–157
 
proteins. This results in peptides that have activity similar to the chemerin 
139–157
 protein 
(Figure 6) (Wittamer V, et al. 2004).  Chemerin peptides were able to compete with 
3
H-
RvE1 for ChemR23 binding, suggesting overlapping binding sites (Arita M, et al. 2005).   
At the amino acid level, human and mouse ChemR23 share 80% identity.  
Chemerin and ChemR23 orthologs can be found in mammals, birds and fish with strict 
conservation of six cysteines hypothesized to be important in disulfide bridging 
(Luangsay S, et al. 2009).   
ChemR23 is expressed on many tissues, including three tissues that are involved 
in mechanisms of RA:  immune cells in peripheral blood, neurons in the brain and 
peripheral nervous system (PNS) (Arita M, et al. 2005) and bone (Methner A, et al. 
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1997).  Among human peripheral blood leukocytes, ChemR23 is most highly expressed 
on monocytes, followed by neutrophils and T lymphocytes (Arita M, et al. 2005). In 
human peripheral blood monocytes, both ChemR23 and COX-2 mRNA expression are 
up-regulated in response to TNF- (Arita M, et al. 2005), which is consistent with RvE1 
as a regulator of resolution of inflammation.  
 
  RvE1 Biological Functions 
 
 RvE1 has pleiotropic biological activities that counteract the three mechanisms of 
RA: inflammation, pain and bone loss.  RvE1 was discovered as a COX pathway lipid 
mediator that had pro-resolving and anti-inflammatory properties (Serhan CN, et al. 
2000). RvE1 inhibits capsaicin-induced spontaneous excitatory postsynaptic currents 
(sEPCs) in patch clamp experiments on dissociated mouse DRG neurons (Park C-K, et 
al. 2011). The RvE1 receptor, ChemR23 is expressed on both osteoblasts (Gao, et al. 
2013) and osteoclasts (Herrera BS, et al. 2008) RvE1 directly increases bone growth and 
mineralization via up-regulation of osteoprotegerin (OPG) (Gao L, et al. 2013), and 
decreases osteoclast differentiation and diminishes dentin resorption (Herrera BS, et al. 
2008).   
 
HYPOTHESIS 
RvE1 or its analogs represent a unique RA therapeutic opportunity because RvE1 
is known to modulate three mechanisms involved in RA pathology and progression:  (1) 
inflammation, (2) inflammatory and neuropathic pain, and (3) joint destruction.  Unlike 
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the currently available therapeutics for RA, an RvE1-based therapeutic has the potential 
to resolve disease and return diseased joints to homeostasis.  
 
 
PUBLISHED STUDIES 
To evaluate RvE1’s potential as an RA therapeutic, there are four major areas of 
exploration: (1) RvE1 action in reducing inflammation and promoting resolution of 
inflammation, (2) RvE1 action in reducing inflammatory and neuropathic pain, (3) RvE1 
action in reducing joint destruction and promoting joint repair, and finally, (4) evaluation 
of RvE1’s drug-like properties. There are no reports of RvE1 used directly as a 
therapeutic in human RA or in animal models of RA.  However, there is ample literature 
evidence of RvE1 used as a therapeutic in both autoimmune and bacterial inflammation 
models, in inflammatory and neuropathic pain models and in joint destruction models. To 
evaluate RvE1 with the current literature, similarities in molecular mechanism of action 
between these models and in RA can be drawn.   
 
RvE1 and Resolution of Inflammation 
RvE1 is efficacious in reversing inflammation in animal models of inflammation, 
including experimental autoimmune animal models such as allergic asthma (Flesher RP, 
et al. 2013) and inflammatory bowel disease (Arita M, et al. 2005), as well as bacterial 
infection such as pneumonia-induced inflammation.  These models share features with 
RA in that they involve activation of macrophages, neutrophils, T cells and B cells.  
Upon infiltration of these activated immune cells into target tissue, they unleash pro-
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inflammatory programs that include up-regulation of pro-inflammatory cytokines TNF-, 
IL-1 and IL-6, antibody production, and translocation of transcription factor NF-B 
from the cytoplasm to the nucleus.  
 
RvE1 and Ovalbumin-induced Allergic Asthma 
The ovalbumin-induced allergic airway mouse model is a well-accepted model of 
human allergic asthma.  In this model, ovalbumin-sensitized mice are challenged with 
low level aerosolized antigen for 4 weeks.  A single moderate level ovalbumin (OVA) 
challenge is administered to mimic a human allergy-induced acute asthmatic episode. As 
with human asthma, mice respond with rapid neutrophil, lymphocyte, eosinophil, and 
macrophage recruitment to the lungs.  The infiltrating immune cells produce pro-
inflammatory cytokines such as TNF- and IL-1, and translocate the pro-inflammatory 
transcription factor NF-B from the cytoplasm to the nucleus.  Over the following 96 
hours, a molecular program to resolve inflammation promotes suppression of 
inflammatory cytokines and down-regulation of NF-B.  In this model, i.p. 
administration of RvE1 2 or 8 hours post-acute challenge resulted in acceleration of the 
resolution program: inflammatory cells in the lung declined, inflammatory cytokine 
expression by activated macrophages decreased, and NF-B translocation to the nucleus 
decreased  (Figure 7) (Flesher RP, et al. 2013). 
Although RA and asthma are autoimmune diseases that affect disparate tissues, 
some of the mechanisms of unchecked inflammation between these two diseases are 
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similar, such as high expression of pro-inflammatory cytokines TNF-, and IL-1, 
antibody production, infiltration of inflammatory immune cells into affected tissue and 
translocation of transcription factor NF-B in activated immune cells.  In the OVA model 
of asthma, RvE1 was able to inhibit inflammation.  In RA, RvE1 may also be able to 
inhibit inflammation through these mechanisms common to both diseases. 
 
RvE1 and Chemically-induced Colitis 
The human autoimmune condition, IBD can be modeled in rodents through 
chemically-induced colitis.  Administration of exogenously produced RvE1 in both 2, 4, 
6-trinitrobenzene sulfonic acid (TNBS)-induced colitis and dextran sulfate sodium 
(DSS)-induced colitis results in protection against inflammation and disease progression 
(Arita M, et al. 2005; Ishida T, et al. 2010). 
In the TNBS-induced colitis model, mice sensitized by skin painting with TNBS 
followed by intrarectal TNBS administration develop bloody diarrhea and weight loss 
which leads to death in >60% of mice treated.  Physiologically, there is significant 
shortening, thickening and ulceration of the colon. Histologically, ulcerations are marked 
by transmural infiltration of inflammatory PMNs, monocytes and lymphocytes.  
Mice pretreated i.p. with 1 g/ mouse RvE1 were protected from TNBS-induced 
colitis. Compared to vehicle controls, RvE1-treated mice had improved survival rates, 
sustained body weight, improved histological scores and reduced inflammatory cells.  
RvE1-treated mice also had significant reduction in molecular markers of disease, such as 
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expression of pro-inflammatory cytokines IL-12 and TNF- (Figure 8), and circulating 
anti-TNBS antibodies (Arita M, et al. 2005). 
The dextran sulfate sodium (DSS)-induced colitis in mice is another chemically-
induced colitis animal model of human inflammatory bowel disease.  In this model, after 
5 days of treatment with 3.5% DSS in drinking water, mice develop bloody diarrhea and 
severe wasting. The colon is significantly shortened and thickened. Transmural 
infiltration of neutrophils and mononuclear cells cause ulcerations in the colon.  In the 
infiltrating immune cells, NF-B p65 Ser276 phosphorylation and translocation to the 
nucleus results in up-regulation of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 
(Ishida T, et al. 2010).   
1 g/mouse RvE1 dosed i.p. for 5 days concurrently with 3.5% DSS in drinking 
water protected mice from DSS-induced colitis.  By day 8, RvE1-treated mice maintained 
90.7 ± 2.4 % of baseline body weight compared with PBS-treated mice the retained only 
78.1 ± 2.6 % baseline body weight. RvE1-treated mice also were protected from DSS-
induced colon shortening and thickening, compared to PBS-treated mice.  
Microscopically, RvE1 treated mice also had significantly fewer neutrophil and 
mononuclear infiltrates in the colon.  RvE1 treatment reduced NF-B p65 Ser276 
phosphorylation and translocation in the distal colon.  In addition, RvE1 also significantly 
reduced transcription of TNF-α, IL-1β, and IL-6 (Ishida T, et al. 2010).   
In both TNBS-induced and DSS-induced animal models of colitis, RvE1 
demonstrated the ability to reduce TNF-α, IL-1β, and IL-6 production and to reduce 
neutrophil and macrophage infiltration into colon tissue.  Although RA and IBS are 
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disparate autoimmune disease affecting different tissues, they share the features of 
uncontrolled inflammation that features high expression of pro-inflammatory cytokines 
such as TNF-α, IL-1β, and IL-6, and infiltration of neutrophils and macrophages into 
affected tissue. 
RvE1 and Pneumonia-induced Inflammation 
In the aspiration pneumonia model, mice receive an acute left lung injury with 
hydrochloric acid followed by challenge with enteric E. coli. Subsequent infection results 
in neutrophil infiltration of the lung, up-regulation of IL-1, IL-6, and monocyte 
chemoattractant protein-1 (MCP-1), and can ultimately lead to death.  Mice pretreated 
with 5g/kg RvE1 showed enhanced clearance of E. coli, significantly decreased 
neutrophil infiltration, significant reduction in pro-inflammatory cytokines and 
chemokines, and marked improvement in survival. RvE1 did not appear to have an anti-
bacterial effect on E. coli in culture, suggesting that RvE1 acts to enhance immunity 
rather than directly inhibit E. coli (Figure 9) (Seki H, et al. 2010).  While other 
autoimmune disease models show that RvE1 can control sterile inflammation, these 
experiments also suggest that RvE1 can play a role in bacteria-mediated inflammatory 
response and resolution.  This suggests that RvE1’s role in inflammation resolution is not 
specific to a disease, but rather a general mechanism to bring an inflammatory response 
back to homeostatic equilibrium. 
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RvE1 and Inflammation in RA 
 The inflammation animal models outlined above have several features in common 
with human RA.  All of these immune responses depend on inflammation that directs 
monocytes and B cells to target tissues.  These immune cells, particularly monocytes, 
produce pro-inflammatory cytokines such as TNF-, IL-6 and IL-1. Activation of these 
cells results in phosphorylation of IB in the cytoplasm and nuclear translocation of the 
transcription factor NF-B. Antibodies are produced in response to an autoantigen or 
bacterial component.  In the animal models, therapeutic use of RvE1 results in not only a 
dampening but a reversal of these inflammatory responses and a return to homeostasis.  If 
a RvE1-based therapeutic could resolve inflammation and return the immune system to 
homeostasis in RA patients, it would represent a paradigm shift in RA treatment. 
 
RvE1 and Analgesia 
When dietary supplements containing EPA, the omega-3 fatty acid precursors of 
type E resolvins, were taken by RA patients for 3-4 months, patients reported significant 
changes in several measures of RA-related pain: decreases in minutes of morning joint 
stiffness, intensity of joint pain, number of painful/tender joints and NSAID consumption 
(Goldberg RJ and Katz J. 2007). 1 ng/mouse RvE1 was more effective than 1 g/mouse 
EPA at reducing nocifensive behavior in the complete Freund’s adjuvant (CFA)-induced 
heat hyperalgesia model (Figure 10) (Xu ZZ, et al. 2010). This suggests that RvE1 could 
be the major component of the analgesic activity in EPA. 
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To understand RvE1’s analgesic potency in inflammatory pain, at least three 
mechanisms should be considered: direct inhibition of inflammation, PNS-mediated 
analgesia, and the central nervous system (CNS)-mediated analgesia. RvE1 has 
repeatedly been shown to directly decrease inflammatory pain by inhibiting 
inflammation, but RvE1 also can directly provide analgesia through PNS- and CNS-
mediated pathways. 
 
RvE1 and PNS-mediated Analgesia 
Local administration of RvE1, at the site of inflammation, has been shown to 
reduce inflammation and pain in well-established rodent models of inflammatory pain.  
Mice pretreated with intraplantar RvE1 showed reduced formalin-induced spontaneous 
pain and reduced carrageenan (CRG)-induced heat hyperalgesia (Xu ZZ et al, 2010). In 
the CRG-induced hyperalgesia model, RvE1 reduced inflammation directly as shown by 
inhibition in neutrophil recruitment and up regulation of pro-inflammatory cytokines such 
as TNF-α, IL-1β, and IL-6.  RvE1 levels could be reduced until the analgesic effect 
remained intact even as neutrophil recruitment and edema increased (Figure 11) (Xu ZZ 
et al, 2010). This suggests that RvE1’s analgesic properties are not solely due to 
inhibition of inflammation. 
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RvE1 and the CNS-mediated Analgesia 
In mice, intraplantar 0.5% formalin administration is characterized by a two-phase 
pain response. The first phase begins immediately after formalin administration and lasts 
for 10 minutes. Duration of licking and flinching is used as a measure of pain. After a 
transient decline in these behaviors, there is second phase of pain that lasts for 30-60 
minutes.  Local anesthetics such as lidocaine can inhibit first phase pain (Abbadie C, et 
al. 1997).  It is hypothesized that the second phase pain is due to activity-dependent 
sensitization of C-fiber nociceptors in the dorsal horn of the CNS (Woolf CJ. 1983).  
Administration of i.t. NSAIDs (Malmberg AB and Yaksh TL. 1992) or morphine (Yaksh 
TL, et al. 2001) inhibits only second phase pain. 
An i.t. dose of 1 ng/mouse of RvE1 was as effective as 100 ng/mouse of 
morphine, an opioid analgesic, or 10 g/mouse NS-398, a selective COX-2 antagonist, at 
reducing formalin-induced 2
nd
 phase, but neither reduced 1
st
 phase response (Figure 12) 
(Xu ZZ, et al. 2010).   This result shows that RvE1 is a potent analgesic that can act 
through CNS-mechanisms. 
Molecular Mechanisms of RvE1 Analgesia  
In vitro cell-based experiments probe the potential molecular mechanism of 
RvE1’s reductions of pain in animal models.  Two possible mechanisms have been 
proposed: (1) RvE1-mediated reduction of TNF--induced inflammation, and 
peripherally and centrally-regulated pain; and (2) RvE1-mediated inhibition of TRPV1. 
RvE1 and TNF- in Analgesia 
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 Apart from inflammatory pain due simply to edema, TNF- appears to have a 
direct role in pain.  The two receptors for TNF-, known as TNF- receptors 1 and 2 
(TNFR1 and TNFR2), appear to play different roles in transmission of inflammatory 
pain.  Both TNFR1
-/-
 and TNFR2
-/-
 mice have heat sensitivity and lamina II neuron 
spontaneous excitatory post synaptic current (sEPSC) responses that are comparable to 
wild type mice. In wild type mice, TNF- evokes heat hyperalgesia and significant 
increase in sEPSC frequency in wild type lamina II neurons.  This TNF--enhanced heat 
hyperalgesia was decreased in both early and late phase pain response for TNFR1
-/-
, but 
reduced only in early phase pain response for TNFR2
-/-
 mice.  At the cellular level, TNF-
-enhanced sEPSC response was completely ablated in lamina II neurons from TNFR1-/- 
mice and reduced in TNFR2
-/-
 mice (Zhang L, et al. 2011).  These data show that TNF- 
can enhance pain response by increasing sEPSC frequency, and there are differing 
contributions between TNFR1 and TNFR2. RvE1 has been shown to down-regulate 
TNF- produced by monocytes.  As a therapeutic, RvE1 or RvE1 analogs have the 
potential analgesic effects by inhibiting inflammation-driven edema or by inhibiting 
TNF- actions on sEPSCs frequency. 
 
RvE1 and TRP Channels in Analgesia 
 
Resolvins have been shown to act through transient receptor potential cation 
(TRP) channels (Caterina MJ, et al. 2000; Dai Y, et al. 2007; Ji RR, et al. 2002).  The 
TRP superfamily members are structurally similar integral membrane proteins that 
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function as ion channels. The 28 identified TRP superfamily members are organized into 
6 subfamilies: TRPC, TRPV, TRPM, TRPA, TRPP and TRPML (Montell C. 2005).  
Two TRV family members stand out as molecular switchboards for a diverse 
array of stimuli.  To date, they are the most studied of the TRP family members. 
Transient Receptor Potential Vanilloid 1 (TRPV1) is the obligate receptor for capsaicin 
and a key receptor for noxious physical heat (Caterina MJ, et al. 1997).  Transient 
Receptor Potential Ankyrin 1 (TRPA1) is expressed on unmyelinated nociceptors, 
suggesting a role in nociception.  Consistent with this posit, TRPA1 is activated by 
burning, irritating compounds, such as allyl isothiocyanate and formalin, and can also 
transduce noxious cold or mechanical force stimuli (Corey DP, et al. 2004; McNamara 
CR, et al. 2007; Story GM, et al. 2003). 
Intraplantar injection of RvE1 is effective in reducing nocifensive behavior 
induced with CAP, a TRPV1 agonist, but not by mustard oil, a TRPA1 agonist. (Xu ZZ, 
et al. 2010).  Patch clamp experiments in lamina II neurons ex vivo in isolated spinal cord 
slices and in dissociated mouse DRG neurons, showed that RvE1 inhibited capsaicin-
induced TRPV1-dependent sEPSCs (Figure 14A) (Park C-K, et al. 2011), but not 
mustard oil allyl isothiocyanate (AITC)-induced TRPA1-dependent sEPSCs (Figure 14B) 
(Park C-K, et al. 2011). Taken together, these results suggest that RvE1 reduces CAP-
induced pain inhibiting TRPV1-dependent sEPSCs. RvE1 does not directly bind TRPV1 
(Xu ZZ, et al. 2010), but there is evidence that RvE1’s known receptor, ChemR23, is co-
localized on TRPV1+ neurons (Figure 15) (Xu ZZ, et al. 2010).  
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RvE1 and ChemR23 in Analgesia 
 
ChemR23, the receptor for RvE1, is co-expressed DRG neurons that express 
TRPV1 (Figure 15) (Xu ZZ, et al. 2010).  Other lines of evidence also point to a possible 
role for ChemR23 in RvE1 analgesia for formalin-induced second phase TRPV1-
mediated pain.  First, RvE1’s analgesic action is abolished with pertussis toxin, a Gi-
coupled GPCR inhibitor, but not with naloxone, an opioid receptor antagonist.  ChemR23 
is a Gi-coupled GPCR.  Second, ChemR23 specific siRNA knockdown inhibited RvE1’s 
analgesic effects.  And finally, chemerin, another endogenous ligand for ChemR23, also 
shows analgesic effects in this model (Xu ZZ, et al. 2010). Potentially, RvE1-binding to 
ChemR23 may inhibit TRPV1 downstream signaling resulting to suppress TRPV1-
dependent sEPCs and pain. 
RvE1 Analgesic Activity in RA 
 
 RvE1 has multiple potential routes to providing analgesia in RA, by acting on the 
immune system to reduce inflammatory pain, or by directly acting on the nervous system 
to quiet sEPSCs.  By directly inhibiting TNF-, RvE1 reduces TNF--mediated edema.  
RvE1 can also down-regulate TNF- expression from immune cells.  Reduction in 
circulating TNF- would translate to less activation of TNFR1- and TNFR2-mediated 
hyperalgesic sEPSCs responses on neurons. RvE1 can also act through the TRPV1 
pathway to quiet hyperalgesic sEPSCs. It is not known if RvE1 can cross the blood-brain 
barrier (BBB); however, i.t. or locally administered RvE1 has been shown to act in the 
CNS- and PNS-mediated analgesia respectively. This suggests that even if an RvE1-
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based therapeutic cannot cross the BBB to affect CNS- mediated pain; it has the potential 
to act locally to inhibit PNS-mediated pain. 
 
RvE1 and Bone Homeostasis 
 Compared to understanding of the role of RvE1 in inflammation resolution, and 
the role of RvE1 in analgesia, the evidence of a role for RvE1 in bone homeostasis is 
relatively recent.  However in both a physical bone injury model, and a bacterially-
induced injury model, RvE1 reverses bone loss. 
 
RvE1 and Uniform Craniotomy 
The uniform craniotomy mouse model is a bone-healing model for physical bone 
injury.  In this model, a 1-mm craniotomy defect is inflicted.  Over two weeks, the injury 
is allowed to heal. The endpoint is a histological measure of the bone recovery as a 
percentage of the area of the original defect.  New bone formation was significantly 
increased in mice that were treated with 100 ng RvE1in PBS, compared with PBS, 
subperiosteal injections over the defect every other day for the 2-week healing period. In 
this model CD11b+ monocytes infiltrate the injured tissue, and osteoblasts form new 
bone.  Both CD11b+ monocytes and osteoblasts endogenously express ChemR23, the 
receptor for RvE1.  To determine which of these cell types was responsible for the RvE1-
accelerated bone regrowth; this model was performed on a CD11b promoter-driven 
ChemR23 transgenic mouse.  In these transgenic mice, CD11b- osteoblasts express only 
endogenous levels of ChemR23 while CD11b+ monocytes overexpress ChemR23.  
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CD11b promoter-driven ChemR23 transgenic showed the same rate of regrowth as wild 
type mice with either RvE1-treatment or PBS treatment (Figure 16) (Gao L, et al. 2013). 
This unexpected result suggested that RvE1-mediated signaling through ChemR23 on 
infiltrating CD11b+ monocytes was not responsible for RvE1-accelerated bone regrowth 
because overexpression of ChemR23 does not further enhance this effect.   
To further address the possibility that RvE1 directly acts on ChemR23 on 
osteoblasts to promote bone growth, investigators applied RvE1 to ex vivo neonatal 
calvarial osteoblast cultures and measured the RANKL/OPG ratio, an indicator 
osteoclast/osteoblast activity. If the RANKL expression is favored, osteoclastogenesis is 
favored, leading to net bone loss.  If OPG expression is favored, osteoblastogenesis is 
favored, leading to net increase in bone volume and density. In the presence of RvE1, the 
bone cultures showed increased expression of OPG, favoring osteoblast action (Gao L, et 
al. 2013). Addition of the pro-inflammatory cytokine IL-6 suppressed RvE1-mediated 
increase in OPG.  Expression of RANKL was not altered with RvE1 in the presence or 
absence of IL-6 in calvarial osteoblast cultures (Figure 17) (Gao L, et al. 2013).  The 
calvarial osteoblast culture data is consistent with the in vivo uniform craniotomy data: 
both sets of data suggest RvE1 directly acts through ChemR23 on osteoblasts to favor 
osteoblast activity and bone growth.   
 
RvE1 and Periodontitis 
RvE1’s effects on bone damage in animal models of arthritis have not been 
reported; however, RvE1’s effects on bone damage have been reported in animal models 
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of periodontitis.  Periodontitis is constellation of inflammation-mediated bone loss 
diseases and has pathological features that are similar to arthritis.  The etiology of 
periodontitis is known to be specific gram-negative bacteria; however, bone loss is 
directed by host inflammatory response through osteoplastic resorption. In the 
Porphyromonas gingivalis ligature rabbit model of periodontitis, P. gingivalis-treated 
ligatures on the second molars results in neutrophil infiltration and osteoclast-mediated 
bone loss over a 6-week course.  Although RvE1 has no antibacterial activity against P. 
gingivalis, topical application of RvE1 to the ligature inhibited alveolar bone loss by 95% 
(Figure 18) (Hasturk H, et al. 2007).  
RvE1 and Bone Homeostasis in RA 
In RA, as in the uniform craniotomy model and the periodontitis model, the bone 
homeostatic equation is skewed toward net bone loss. If RvE1 can up-regulate OPG in 
RA-affected bone, as it does in the bone culture experiments, this would serve to skew 
the bone homeostasis equation back toward bone regeneration.   
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Rodent models of Rheumatoid Arthritis 
 
Animal models have been proven to be an essential tool in understanding the 
pathogenic mechanisms of RA. Several rodent models have been developed, each with its 
limitations and insights.  Broadly, RA animal models can be divided into two categories: 
(1) exogenously induced models of RA, and (2) genetically modified spontaneous models 
of RA (Asquith DL, et al. 2009).  
 
Exogenously Induced Models of RA 
The first category, exogenously induced models of RA, includes the collagen-
induced arthritis model (CIA) (Courtney JS, et al. 1980; Trentham DE, et al. 1977), the 
collagen antibody-induced arthritis model (CAIA) (Rowley MJ et al, 2008; Stuart JM and 
Dixon FJ. 1983), the antigen-induced arthritis model (AIA) (Brackertz D, et al. 1977a; 
Brackertz D, et al. 1977b), the zymosan-induced arthritis model (Keystone EC, et al. 
1977), and arthritis models induced with non-immunogenic adjuvants (Holmdahl R, et al. 
2001). 
  Collagen-induced Arthritis (CIA) 
 
 Collagen-induced arthritis is considered the gold standard in arthritis animal 
models. As with human arthritis, this model features breach of tolerance to an 
autoantigen against collagen. While the model was first described in rats (Trentham DE, 
et al. 1977), it can also be performed in mice that carry the MHC class II haplotype I-A
q
 
or I-A
r
 (Courtenay JS, et al. 1977; Wooley PH, et al. 1985) and in non-human primates 
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(Cathcart ES, et al. 1986) making it a useful model for allometric scaling and human dose 
projection. Immunohistochemical analysis of articular joints through the CIA time course 
show that while T-lymphocytes are present and secreting IFN- and IL-17A during 
initiation of disease, these cells become scarce during clinical disease.  In contrast, 
macrophages infiltrate into the synovial lining and pannus early in disease initiation and 
appear to persist through all stages of disease.  By immunohistochemical staining, these 
inflammatory macrophages secrete TNF-, IL-6 and TGF- through the disease course 
(Table 5) (Mussener A, et al. 1997).  Maximal expression of macrophage-derived IL-1 
and IL-10 transcripts in synovial tissue correlate with peak CIA disease score (Stasiuk 
LM, et al. 1996). These observations suggest that CIA initiation is orchestrated by TH1 
lymphocytes recruiting macrophages into the synovia, and that these macrophages sustain 
disease by producing TNF-, IL-6 and IL-1Luross JA, et al. 2001).  
 
  Collagen Antibody-induced Arthritis (CAIA) 
 
Serum from collagen-immunized susceptible strains of mice can cause arthritic 
disease when transferred to either susceptible or resistant strains of mice.  
Immunohistochemical characterization of this serum transfer model showed that donor 
immunoglobulins were localizing on recipient joints and other cartilage (Stuart JM, et al. 
1983). Collagen antibody-induced arthritis (CAIA) can be induced in most strains of 
mice by immunizing with purified anti-collagen type II (anti-CII) antibodies and results 
in a fast 48-hour onset severely erosive arthritis.  Macrophages and PMN cells have been 
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implicated in disease, while T- and B-lymphocytes do not appear to play a role (Rowley 
MJ, et al. 2008). 
 
  Antigen-induced Arthritis (AIA) 
 
 In the antigen-induced arthritis model, mice are immunized with methylated 
bovine serum albumin (mBSA) in complete Freund's adjuvant with B pertussis vaccine, 
and challenged with an intra-articular injection of mBSA in saline in the knee joint on 
day 21 post-immunization. Susceptible strains of mice develop a chronic, antigen-
specific, T-cell driven arthritis. While C57BL/6 and BALB/c mice are susceptible, the 
CBA strain is relatively resistant.  Differences in MHC class II haplotype only partially 
explain this disparity, as larger immunogenic doses could overcome lower humoral 
responses. In vivo radioisotopic assay showed that delayed-type hypersensitivity (DTH) 
responses to mBSA differed between the strains. CBA mice had a quick, weak response 
that dissipated quickly, while C57BL/6 mice had a later, more sustained DTH response. 
In this model, arthritis susceptibility depends on two factors, MHC class II haplotype and 
the strength of T-lymphocyte dependent DTH response (Brackertz D, et al. 1977a; 
Brackertz D, et al. 1977b). 
  Zymosan-induced Arthritis 
 
Zymosan, a glucan of repeating glucose units, binds to macrophages via Toll-like 
receptor 2 (TLR2) to activate complement via the alternative pathway, up-regulate IL-1 
and TNF- cytokines, promote NF-B translocation to the nucleus, and mobilize 
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arachidonate to generate sterile inflammation (Sato M, et al. 2003).  Zymosan also 
increases cyclin D2 to induce macrophage proliferation.  Intra-articular (i.a.) injection of 
zymosan particles into mouse knee joints results in chronic inflammatory arthritis 
characterized by mononuclear cell infiltration and synovial hypertrophy.  In contrast, i.a. 
injection of latex particles elicits a mild, transient inflammatory reaction (Keystone EC, 
et al. 1977). 
  Arthritis Models Induced with Non-immunogenic Adjuvants 
 
Finally, chronic relapsing arthritis can be induced in rats using non-immunogenic 
adjuvants such as mineral oil, pristane and squalene (Holmdahl R, et al. 2001). These 
arthritogenic adjuvants do not contain MHC binding peptides, yet disease is both MHC-
dependent and T cell-dependent. While this suggests that an endogenous peptide or 
peptides must be involved, none have been discovered to date (Holmdahl R, et al. 2001). 
Mice or rats that are repeatedly injected i.p. with pristane, a natural saturated terpenoid 
alkane derived from shark liver oil, develop some biomarkers of human RA such as high 
levels of circulating RF and anti-CII antibodies.  However, these animals also develop 
plasmocytomas in the peritoneal cavity, which are not common in human RA, suggesting 
a possible non-concordant mechanism (Wooley PH, et al. 1989).  In rats, arthritis induced 
with single subdermal injection of squalene, a triterpene adjuvant derived from shark 
liver oil, generates T-lymphocytes that express IL-1 and IFN-By day 8 post-injection, 
these T-lymphocytes are arthritogenic and can transfer disease when adoptively 
transferred to naïve rats (Holm BC, et al. 2004). 
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Genetically-modified spontaneous models of RA 
The second category, genetically-modified spontaneous models of RA, includes 
the TNF- transgenic mouse (Keffer J, et al. 1991), the K/BxN mouse (Kouskoff V, et 
al. 1996), the human DR4-CD4 transgenic mouse (Eming R, et al. 2002; Fugger L, et al. 
1994), the IL-1 receptor antagonist
-/-
 mouse (Koenders ML, et al. 2008), and the DNase 
II
 –/-
 IFN-IR 
-/- 
mouse (Kawane K, et al. 2006). 
  The TNFtransgenic mouse 
 
The 3’ untranslated region of the human TNF- gene plays a role in regulating 
transcription of TNF-. Transgenic mice expressing intact 3’ untranslated region with the 
full human TNF- gene have low constitutive TNF- expression, but can respond to 
endotoxin challenge with macrophage-specific TNF- secretion. However, when the 3’ 
untranslated region is replaced with the 3’ untranslated region from human -globulin 
gene, transgenic mice with this modified 3’ region constitutively express high levels of 
TNF-, and develop chronic inflammatory arthritis with 100% penetrance by between 
weeks 3 and 4 post-birth (Keffer J, et al. 1991).  This disease is characterized by severe, 
symmetric swelling of joints, and PMN and lymphocytic inflammatory infiltration of the 
synovial space, which are consistent with human RA.  However, these mice never 
develop detectable levels of circulating anti-RF. Treatment of arthritic mice with 
monoclonal anti-TNF- completely eliminates disease (Keffer J, et al. 1991).   
  The K/BxN mouse  
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The K/BxN model is a complex model of rheumatoid arthritis that was 
serendipitously discovered when the TCR transgenic KRN line was crossed with MHC 
class II A
g7
-transgenic mice (Kouskoff V, et al. 1996). K/BxN mice develop severe, 
erosive arthritic disease characterized by high serum anti-glucose-6-phosphate isomerase 
(GPI) antibodies, IL-1- and TNF--mediated complement cascade activation, 
recruitment of neutrophils and macrophages to joints, and mast cell degranulation 
(Matsumoto I, et al. 2003; van Gaaleen, et al. 2004). Serum from these mice can transfer 
disease to several strains of naïve mice. Other known RA-associated autoantibodies, such 
as anti-RF, anti-CCP and anti-CII, target the cartilage, so the connection to the resulting 
joint inflammation is easy to understand.  GPI, on the other hand, is ubiquitously 
expressed and yet in this model, inflammation is still limited to joints. Subsequent to the 
publishing of the K/BxN model, human RA patients were tested for serum anti-GPI 
antibodies.  In one study, as high as 64% of human RA patients not only have serum anti-
GPI antibodies, but highly somatically mutated anti-GPI antibodies associated with 
synovial endothelium and joint-infiltrating neutrophils (Schaller M, et al. 2001). 
Hypermutation suggested affinity maturation that repeatedly drove higher affinity to the 
target GPI.  However, unlike autoantibodies specific for cartilage components, which 
bound to cartilage via antigen-specific hypermutated regions, anti-GPI antibodies bound 
to synovial endothelium and neutrophils via their Fc regions. This suggested that antigen 
specificity was not targeting these autoantibodies to the joints. Transfer of K/BxN serum 
to mice deficient in FcR, complement 5a receptor (C5aR) or CD11a/LFA-1 resulted in 
protection from disease relative to transfer into a wild type host.  Transfer of K/BxN 
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serum into mice with a neutrophil-specific deficient for IL-1 or LTB4 resulted in a 
diminution of disease.  Together these results suggest that FcR, C5aR and CD11a/LFA-1 
function are essential, and IL-1 and LTB4 function contribute to anti-GPI-mediated 
arthritis (Monach PA, et al. 2010). 
  The Human DR4-CD4 Transgenic Mouse 
 
In human RA, genetic susceptibility to disease is increased with the HLA class II 
allele HLA-DR_0401.  To create a mouse model to mimic this, four separate transgenes 
are required: (1) HLA-DR_0401, the human HLA class II allele, (2) HCgp-39, an RA-
related human auto antigenic protein, (3) the human T cell receptor (TCR) specific for the 
HCgp-39 epitope in the context of HLA-DR_0401, and (4) human CD4, the human T 
helper cell TCR-accessory molecule.  This model is used to study the breach of tolerance 
mechanisms that initiate disease (Eming R, et al. 2002; Fugger L, et al. 1994). 
  The IL-1R antagonist
-/-
 Mouse 
 
In IL-1 receptor antagonist (IL-1Ra)-/- BALB/c mice, unopposed IL-1 receptor 
signaling, in combination with environmental stimuli, drive progressive arthritis.  IL-
1Ra-deficient mice develop arthritic disease, with an onset at 3 weeks of age, 
characterized by inflamed hind limbs, high levels of IL-1, TNF- and IL-17A in serum 
and synovial fluid, increased numbers of TH17 cells in serum and synovial fluid, and 
accelerated bone erosion (Koenders ML, et al. 2008).   
  The DNase II
- /-
IFN-IR 
- /-
 Mouse 
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DNase II / IFN-IR double deficient
 
mice and induced DNase II-deficient mice 
develop a severe polyarthritis.  These mice have TNF--dependent inflammation, high 
levels of circulating anti-CCP antibodies and rheumatoid factor.  It is hypothesized that 
inappropriate cytokine release is precipitated by DNase II-deficiency-mediated 
incomplete DNA disposal in macrophages (Kawane K, et al. 2006). 
 
 RvE1 Evaluation in an RA Animal Model 
 Collagen-induced arthritis is an appropriate animal RA model for RvE1-based 
therapeutic testing.  This is an established and well-studied model with clinical, cellular 
and molecular features that mimic human RA disease course.  Unlike genetic models like 
the TNF- transgenic or the IL-1 antagonist -/- mouse, this model has a full spectrum of 
immune mediators contributing to disease progression.  Unlike the DR4-CD4 transgenic 
mouse that focuses on disease initiation, DNase II
 -/-
 IFN-IR 
-/- 
mouse that focuses on 
macrophage dysfunction (Kawane K, et al. 2006), or the AIA model that focuses on post-
antibody disease progression (Brackertz D, et al. 1977a), the CIA model looks at the full 
time course of disease progression Luross JA, et al. 2001). 
The disease score in the CIA model is based on the number and severity of 
swollen joints, and is roughly similar to the disease activity score (DAS) used in 
assessment of RA in human patients. While this measure is subjective, it can be used to 
assess whether RvE1 treatment can reduce the overall clinical disease score. Pilot 
experiments looking at CIA disease score over disease course for animals treated i.p. with 
PBS vehicle or RvE1 should determine if an RvE1 therapeutic is viable for the treatment 
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of RA.  The dose and the timing of dose administration would have to be optimized.  
Inflammatory markers, such as serum cytokine expression, NF-B translocation and 
kinetics of immune cell infiltration into the joints, are well-characterized in this model.  
The kinetics and severity of bone erosion as measured by x-ray radiography have also 
been well studied in CIA. 
  
Pharmacological Challenges of RvE1 Therapeutics 
The Synthesis Challenges of RvE1 
 
 Multiple possible routes for the synthesis of bioactive RvE1 have been reported in 
the literature. Early isolation of RvE1 was achieved through isolation of biogenic RvE1 
from plasma (Serhan CN, et al. 2000). Biogenic RvE1 also can be isolated from Candida 
albicans (Haas-Stapleton EH, et al. 2007). And finally, RvE1 can be produced through 
stereospecific chemical synthesis (Arita M, et al. 2005) 
Early biogenic preparation methods of RvE1 were low yield as concentrations of 
RvE1 are only 0.1-0.4 ng/ml in healthy human or mouse plasma (Mas E, et al. 2012; 
Serhan CN, et al. 2000). Although RvE1 concentrations have not been reported in 
conventional farm animals, it is difficult to imagine biogenic purification from plasma 
could be commercially viable.  However, in human milk, RvE1 precursor 18R-HEPE and 
RvE1 were measured at between 4-12 ng/ml, at least 100 times plasma levels, and were 
stable in milk for 330 days (Weiss GA, et al. 2013). Again, RvE1 levels in milk from 
conventional farm animals have not been reported. However, dietary methods of 
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increasing -3 fatty acid concentrations in goat, sheep and cow milk are known 
(Moghadasian MH. 2012), although whether this also leads to increases in RvE1 is not 
known.  Currently, isolation of biogenic RvE1 from plasma or milk is not possible on a 
commercial scale.  However, in conjunction with transgenic COX or 5-LO expression, it 
may be feasible in the future to harvest drug-manufacturing quantities of biologically 
synthesized RvE1 from animal milk. Perhaps more importantly, evidence that RvE1 is 
stable in milk suggests that oral administration of RvE1 may be viable. 
Biological synthesis of RvE1 is another potential route.  Candida albicans is 
fungus that resides commensally on human epithelial surfaces, but can cause pathogenic 
inflammation. RvE1 synthesized by EPA-fed C. albicans or by human cells is chemically 
identical. C. albicans-derived RvE1 also has the same anti-inflammatory activities as 
human-derived RvE1, including decreased interleukin-8 (IL-8)-induced neutrophil 
chemotaxis, increased neutrophil phagocytosis and production of reactive oxygen species 
(ROS) (Haas-Stapleton EH, et al. 2007).   It is thought that RvE1-induced clearance of C. 
albicans may represent a symbiotic system by which C. albicans can induce the host’s 
immune system to return fungal homeostasis to commensal status. Haas-Stapleton et al 
do not reveal the yield of RvE1 from C. albicans cultured in the presence of EPA, but 
they note that RvE1 is the most abundant of many pro-resolution mediators discovered in 
these cultures. 
The traditional manufacturing of a small molecule drug is though chemical 
synthesis.  The chemical synthesis of bioactive RvE1 is a well-established protocol that 
requires sequential coupling of three stereochemically pure isomers to form an acetylenic 
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intermediate which can be selectively hydrogenated to form a stereochemically pure 
RvE1 (Figure 19) (Arita M, et al. 2005).  
 
The Stability Challenges of RvE1  
 RvE1 is structurally metabolically unstable because it contains many reactive 
double bonds and hydroxyl groups (Arita M, et al. 2005; Hong S, et al. 2008). The RvE1 
metabolome, metabolically derived products of RvE1 can reduce and even eliminate the 
pro-resolution potency of RvE1 (Figure 20) (Hong S, et al. 2008).  15-
hydroxyprostaglandin dehydrogenase (15-PGDH) catalysis of NAD
+
-linked oxidation of 
the 15 (S)-hydroxyl group of eicosanoids, such lipoxins and prostaglandins, is the major 
route of inactivation for these COX pathway pro-inflammatory mediators, (Ensor CM 
and Tai HH. 1995). 15-PGDH can also inactivate RvE1 through a similar reaction to oxo 
metabolites (Arita M, et al. 2006). In theory chemical modification to block 
dehydrogenation of RvE1 and prevent reduction of its conjugated double bonds may 
reduce 15-PGDH-catalyzed metabolism resulting a more stable pro-resolution agonist.  
 
Route of Administration 
 The scientific research on the many biological actions of RvE1 is based on animal 
models, in which RvE1 is injected, or in vitro experiments, in which RvE1 is applied 
directly to cells.  Traditionally, the best route of administration for a commercially viable 
drug would be oral.  However, the RA patient population has accepted biologic therapies 
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that require i.v. or s.c. injection.  In these cases, the therapeutic benefit of the biologic 
outweighed the discomfort of injection.  RvE1 may offer an even greater therapeutic 
benefit than current biologic therapies.  Therefore, a non-oral route of administration may 
be commercially feasible. 
Toxicity Challenges for RvE1 
 There have been no reported toxicities with RvE1 or RvE1 analogs tested in 
animal models or in humans.  This is potentially because the efficacious dose of RvE1 is 
very low, in the nanomolar range, because as a pro-resolving mediator it is not expected 
to be toxic.  Indeed, in a therapeutic dosing scheme, RvE1-based therapeutics could 
potentially be used as a short-term therapy that resets homeostasis.  Although the lack of 
over toxicity is an encouraging pharmacological property, this presents a challenge for 
pre-clinical toxicology studies.  In a typical toxicology study, the dose is escalated 
beyond the therapeutic dose until toxic effects can be observed.  Although a synthetic 
RvE1 (Rx-10001) and a proprietary synthetic RvE1 mimetic (Rx-10045) have completed 
Phase 1 (NCT009401018) (Resolvyx Pharmaceuticals, Inc. 2009) and Phase 2 
(NCT00799552) (Resolvyx Pharmaceuticals, Inc. 2008) clinical trials, respectively, the 
results were not reported.  However, Rx-10045 entering Phase 2 suggests that Phase 1 
findings were favorable. 
Current Clinical Development Activity for RvE1 
Resolvyx Pharmaceutics, in cooperation with Celtic Therapeutics, reported 
development of two therapeutics based on RvE1:  (1) Rx-10001, a synthetically produced 
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RvE1, (2) Rx-10005, a methyl ester of RvE1, and Rx-10045, a proprietary RvE1 
mimetic. 
Resolvyx chose to target in a mouse dry eye model, as their first target disease 
indication.  Dry eye is a good first indication to test a RvE1 therapeutic for several 
reasons: (1) the target tissue, the cornea, is accessible to topical application, by-passing 
the short half-life issue; (2) inflammation can be assessed via corneal permeability; and 
(3) this model of dry eye is predicative of human dry eye.  C57BL/6 mice treated with 
systemic scopolamine and exposed to air draft and low humidity for 16 hours per day for 
5 days develop increased corneal permeability to Oregon Green Dextran and reduced 
conjunctival goblet cell density. Mice treated topically with RX-10001 showed reduced 
corneal Oregon Green Dextran staining and maintenance of goblet cell density when 
compared to vehicle controls.  The pro-drug form of RvE1, RX-10005, enhanced drug 
delivery into the cornea, suggesting that modification to the methyl ester form of RvE1 
may have increased drug utility for RvE1 to treat dry eye (Figure 21) (de Paiva CS, et al. 
2012).   Resolvyx completed a Phase I clinical trial with Rx-10001, a synthetic RvE1, in 
healthy volunteers in 2009 (NCT009401018) (Resolvyx Pharmaceuticals, Inc. 2009), 
and a Phase II clinical trial with RX-10045, the RvE1 mimetic, in dry eye patients in 
2010 and 2012 (NCT00799552, NCT01675570) (Resolvyx Pharmaceuticals, Inc. 
2009, C.T. Development America, Inc., 2012). Currently, Auventx, the re-branded 
incarnation of Celtic Therapeutics, reports on its website that RX-10045, a proprietary 
RvE1 mimetic has successfully completed the Phase II study in allergic conjunctivitis 
patients in 2012 (NCT01639846) (C.T. Development America, Inc., 2012) and will soon 
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enter a Phase III randomized, placebo-controlled, multicenter dry eye study 
(www.auventx.com).  The Resolvyx (www.resolvyx.com) and Auventx websites also 
suggest that RvE1 therapeutics RX-10001 and RX-10005 will be tested in clinical trials 
in a myriad of autoimmune diseases such as asthma, IBD, RA, and various other 
indications. Clinical trial dose, formulation, and trial outcome data has not been disclosed 
publically for any RvE1 therapeutic. 
 
DISCUSSION 
RvE1 is an endogenously produced lipid mediator that activates the resolution of 
inflammation, analgesia and bone homeostasis, making it an attractive potential 
therapeutic for RA.  Although well-established animals of RA exist, current research has 
not directly tested RvE1 in these models. However, RvE1 administration is efficacious in 
inhibiting other in vivo models of autoimmunity, models of pain and models of joint 
destruction.  In vitro assays have also confirmed that RvE1 is an effective inhibitor of 
inflammatory cytokine production, inflammatory cell migration, pain receptor-mediated 
cation channel signaling, and osteoblast activation.  Extensive research into RvE1 
molecular mechanisms provides a rich platform of in vivo and in vitro drug development. 
Several RvE1 production methods are known, but scaling these methods to drug 
production quantities may be challenging.  Protocols for detection of RvE1 and its 
metabolites in serum are established.  In most animal models, nanomolar RvE1 
administration elicits pro-resolving, analgesic and osteogenic effects with no apparent 
toxicity in animals.  Although drug discovery efforts will be complicated by evaluating 
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three RA mechanisms in vitro and in vivo, the resulting therapeutic has the potential to 
treat all three mechanisms of RA and reverse disease damage without toxicity. 
 
RvE1 Drug Development Strategies 
As a potential therapeutic, endogenous RvE1 has many favorable characteristics:  
nanomolar binding affinity for its target ChemR23 (Kd = 11.3 nM) (Arita M, et al. 2005), 
and a nanomolar potency in animal models of inflammation (Arita M, et al. 2005; 
Flesher, RP et al, 2013; Ishida T, et al. 2010; Seki H, et al. 2010), pain (Xu ZZ, et al. 
2010) and bone repair (Gao L, et al. 2013). Endogenous RvE1 also has significant drug 
development challenges that need to be addressed in a RvE1-based mimetic: RvE1 is 
metabolized to a biologically inactive oxo-18-RvE1 within 2 hours in vivo (Figure 22) 
(Arita M, et al. 2006), as a lipid mediator it highly lipophilic and unstable in aqueous 
solutions, the pharmacokinetics of RvE1 are not well understood especially in joints, the 
RvE1 pathway is not validated as target in rheumatoid arthritis, and the translation 
between mouse and human biology is not known.  
Traditional drug discovery uses high throughput screening (HTS) of large 
chemical libraries to identify initial drug candidate hits and structure-activity relationship 
(SAR) and structure-property relationship (SPR) driven optimization to improve drug-
like properties.  However, in this case, an endogenous molecule, RvE1, could be used 
directly as the drug product or a starting point for drug development.   
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Proof of Pharmacology: RvE1 in CIA 
 Before an RvE1 pathway drug development can be considered, endogenous RvE1 
should be tested in a mouse model of rheumatoid arthritis as a proof of pharmacology. 
Although the efficacy of RvE1 has been shown in other animal models of inflammation, 
pain and bone damage, there has not been a published study of RvE1 in an animal model 
of RA.  In addition, because there are no approved RA therapies targeting RvE1 or 
ChemR23, there is no proof of pharmacology in humans. 
 Of the three mechanisms of RA, inflammation and bone erosion are routinely 
quantitatively measured in animal models of RA, but pain is not.  CIA has a full course of 
RA disease that models the human RA time course. Inflammation can be assessed 
through disease progression via measurement of inflammatory cytokines IL-6 and TNF- 
in serum, or as an endpoint measure by histologically assessing inflammatory cytokine 
expression and inflammatory cell infiltration into joints. Joint damage can be measured 
by x-ray radiography in the hind limbs of anesthetized animals through disease course, or 
as a very precise endpoint measure by microscopically quantitating bone loss in x-ray 
radiographs of dissected forelimb and hind limbs.  Pain is not typically measured in this 
or any RA model.  
To determine analgesia in animals, a pain stimulus, such as heat, is given and the 
pain response, such is duration of nocifensive behavior, is measured (Figure 10) (Xu ZZ, 
et al. 2010).  In the presence of an analgesic, the response should be significantly 
diminished.  Arthritis should cause hyperalgesia, so care would have to be taken to 
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compare naïve animals, CIA-induced PBS vehicle-treated animals, and CIA-induced 
RvE1-treated animals. 
Analysis of proof-of-pharmacology for RvE1 in CIA should include optimization 
of RvE1 dose and RvE1 dose timing, and should include comparison to methotrexate and 
TNF- inhibitors.  If proof-of-pharmacology for RvE1 in CIA is achieved, further 
targeted modifications to RvE1 may be pursued to improve potency and pharmacological 
properties such as stability and manufacturability. 
 
Drug Development Screening Funnel 
 Although RvE1 activity has been characterized in many in vitro and in vivo 
assays, many are time-consuming and low throughput.  Therefore, strategic chemical 
modifications to RvE1, rather than a large HTS approach are preferable.  The first 
priority gate is to improve metabolic stability while retaining or maintaining binding to 
ChemR23.  This requires stability assays and binding assays be done in parallel. 
Secondly, in vitro functional assay should be done on a triaged subset of compounds that 
pass the first gate. Next, compounds that pass this secondary gate should be prioritized 
for in vivo assays: pharmacokinetic studies, followed by efficacy studies in CIA, and 
toxicity. 
 
Increasing RvE1 stability 
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The half-life of RvE1 is ~2 hours (Figure 22) (Arita M, et al. 2006).  The major 
RvE1 products from human blood were 10,11-dihydro-RvE1, 18-oxo-RvE1, and 20-
hydroxy-RvE1.  Mouse kidney and liver generated more 18-oxo-RvE1 than other RvE1-
derived metabolic products. RvE1 is converted to 18-oxo-RvE1 in vitro by human 
recombinant 15-prostaglandin dehydrogenase (Figure 22) (Arita M, et al. 2006). 
Inhibition of RvE1 catabolism to increase RvE1’s half-life could potentially be achieved 
by making a catabolically resistant RvE1 analog.  Inhibition of RvE1 catabolism by 
modification of RvE1 can be achieved by making a catabolically stable but biologically 
active analog.  Indeed, the RvE1 analog, 19-(p-fluorophenoxy)-RvE1 methyl ester 
appears to fit this profile—it is resistant to 15-PGDH catabolism, but retains activity in an 
in vivo zymosan A-induced inflammation model (Arita M, et al. 2006).  Thus, 19-(p-
fluorophenoxy)-RvE1 show that it is possible to design a potent anti-inflammatory, pro-
resolution mediator that is more metabolically stable than endogenous RvE1.  
An easy, in vitro enzymatic assay to measure the major RvE1 catabolic assay 
exists.  15-PGDH-catalyzed catabolism of RvE1 requires NAD+ as a co-factor.  As 
NAD+ is converted to NADH, the 340nM absorbance increases and can be measured 
easily by spectrophotometer (Figure 22) (Arita M, et al. 2006).  As the first step, 
chemical modifications to RvE1 can be easily assessed for resistance to 15-PGDH 
catabolism.  
 
ChemR23 Binding Assay 
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3
H-RvE1 bound to ChemR23-transfected HEK with a high affinity (Kd of 11.3 
nM) (Arita M, et al. 2005).  Unlabeled RvE1 mimetics can be assayed for ability to 
compete for ChemR23 by measuring the decrease in 
3
H-RvE1.  
3
H-RvE1 and human 
ChemR23-transfected HEK cells are commercially available.   
Both the stability assay and the binding assay can be used as the first line assays 
to assess the largest number of RvE1 mimetics.  Compounds that have improved 15-
PGDH resistance and improved or maintained ChemR23 binding should be further 
assessed for in vitro function. 
 
In vitro Functional Assays 
 
RvE1 can target three different functional mechanisms; therefore, at least three 
functional assays should be developed to fully assess potency.  RvE1 function on 
promotion of inflammation resolution, inhibition of pain, and inhibition of bone loss 
should all be explored as follows.  While these readouts may be best assessed through in 
vivo models, for initial screening, in vitro assays offer a less complex assay, higher 
throughput, and shorter assay times.   
 
In vitro NF-B activation in ChemR23-transfected HEK 
    
In immune cells, the anti-inflammatory, pro-resolving activity of RvE1 is 
mediated through ChemR23. Human ChemR23-transfected HEK cells that have an NF-
B-luciferase reporter will luminesce when NF-B is activated by TNF-.  TNF--
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induced luciferase activity in these cells is inhibited by RvE1 (Figure 4) (Arita M, et al. 
2005).  RvE1 mimetics can be compared to native RvE1 in this assay to determine if they 
are likely to inhibit inflammation in vivo.   
In vitro RANKL/OPG Assay 
 
 The in vitro activity of RvE1 analogs on bone can be measured using neonatal 
mouse calvarial primary bone cultures grown in the presence of ascorbic acid, -
glycophosphate and vitamin D3. At day 10, cultures are stimulated with IL-6 and IL-6 
receptor in the presence of RvE1 analog or vehicle. Native RvE1 can be used as a 
positive control.  48 hours post-stimulation, supernatants can be analyzed for RANKL 
and OPG via ELISAs that are commercially available (Figure 17) (Gao L, et al. 2013).  
Compared to supernatants from vehicle control-treated cultures, supernatants treated with 
RvE1 or analogs with RvE1 activity should have the same concentration of RANKL and 
a higher concentration of OPG (Gao L, et al. 2013). 
In vitro sEPSC Assay  
 
 The TRPV1 agonist capsaicin can evoke nocifensive behavior in vivo (Xu ZZ, et 
al. 2010) and can increase sEPSC frequency in DRG neuron in vitro (Park C-K, et al. 
2013) which can be inhibited with RvE1.  This in vitro capsaicin-elicited sEPSC patch 
clamp assay can be used as a surrogate readout to test RvE1 analogs for analgesic 
activity.  Dorsal root ganglion cells isolated from CD1 mice can be cultured on glass 
cover slips in neuroblasal defined medium with 2% B27 supplement for 24 hours. Inward 
currents can be measured with room temperature whole-cell current-clamp recordings 
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holding the potential at -60mV (Figure 14) (Park C-K, et al. 2013). Capsaicin-elicited 
increases in sEPSC frequency should be unaffected in the presence of PBS vehicle, but 
should be diminished with RvE1 or with analogs with RvE1 activity. Due to the time-
intensive nature of this assay, it should only be used to assess compounds that showed 
positive results in the other in vitro activity assays. 
 
In vivo Functional Assays 
Compounds that show in vitro functional activity as potent as or more potent than 
endogenous RvE1 should be further tested in in vivo assays: pharmacokinetic studies, 
followed by efficacy studies in CIA, and toxicity. 
 
Pharmacokinetics 
A liquid chromatography-ultraviolet-tandem mass spectrometry (LC-UV-MS-
MS) method has been developed to detect RvE1 and other lipid mediators in biological 
fluids (Lu Y, et al. 2005).  Initially compounds should be tested i.v. to determine 
pharmacokinetic characteristics. Compounds with increased in vivo half-life, improved 
joint tissue penetration, or decreased clearance should be used to make further compound 
structure improvements and a limited number of representatives of compound classes 
should be further assessed in CIA. As testing progresses, the bioavailability of 
compounds given s.c. or p.o. should be evaluated as these are more attractive treatment 
options. 
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CIA 
CIA is a well-established mouse model of rheumatoid arthritis. Initial disease 
studies should assess compounds for decreased clinical disease score, delayed onset of 
disease.  Inflammation can be evaluated by measuring serum IL-6 and TNF- 
throughout, or through endpoint histology to assess inflammatory cytokine expression 
and inflammatory cell infiltration into joints. Joint damage can be assessed through x-ray 
radiography. Although pain is not typically measured in CIA, efficacy of compounds in 
analgesia could potentially be assessed by decrease in heat-induced hyperalgesia. 
As candidates progress, CIA studies can be modified.  Initially, compounds 
should be tested prophylactically and dosed i.v. to allow the highest bioavailability and 
best chance at efficacy in this model.  As compounds are further studied, s.c. and p.o. 
administration, therapeutic dosing, and short term dosing should be explored.  Ultimately, 
a once-a day p.o. short-term therapeutic dose that allows animals to achieve remission 
and reversal of disease would be optimal. 
A short term dosing schedule would also help answer some of the questions about 
effects of chronic RvE1 mimetic dosing. 
 
CONCLUSION 
 A RvE1-based therapeutic has the potential to be a first-in-class therapeutic that 
targets the three main mechanisms of rheumatoid arthritis:  inflammation, pain and joint 
damage.  Endogenous RvE1 has three biological activities: an anti-inflammatory pro-
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resolving activity, a potent analgesic activity and enhancement of osteoblasts.  These 
activities would not only alleviate symptoms of RA, they have the potential to reverse 
disease, resolve inflammation, and restore damaged joints. 
 Although there are no direct reports of RvE1 or RvE1-based therapeutics in RA or 
animal models of RA, there are reports of RvE1 used therapeutically in animal models of 
inflammation, pain, and bone damage as well as clinical applications of RvE1 
derivatives. These studies have provided a foundation of data that supports the efficacy of 
RvE1 in inhibiting and reversing inflammation, pain and bone damage in vivo.  In 
addition, there are in vitro assays that confirm RvE1’s actions on these three mechanisms 
on a molecular and cellular level.  Well-studied animal models of RA, particularly 
collagen-induced arthritis, could be used as proof-of-pharmacology for an RvE1-based 
therapeutic in RA.  Further chemical structural changes could be assessed in established 
in vitro assays for 15-PGDH stability, ChemR23 binding, and in vitro potency.   
Compounds that showed improved compound stability and in vitro functional activity can 
be further assessed in vivo to determine pharmacokinetic characteristics, and efficacy in 
CIA with inflammatory, bone damage and pain readouts.   
RA is an autoimmune disease driven by chronic inflammation that results in joint 
damage and debilitating pain.  Although there are many RA therapies available, most are 
focused providing analgesia or inhibiting inflammation. A RvE1-based therapeutic has 
potential to not only inhibit inflammation, but may also coordinate a pro-resolution 
program that may return the immune system to a normal homeostatic state.  A RvE1 
mimetic also has the potential to restore joints by favoring osteoblastogenesis rather than 
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osteoclastogenesis.  Finally, a RvE-1 therapeutic has the potential to provide analgesia, 
not just through inhibiting TNF--mediated inflammatory pain, but by acting on central 
and peripheral nociceptive neurons to inhibit TRPV1-mediated pain.  Thus, a RvE1 
mimetic with increased stability and potency relative to endogenous RvE1 should result 
in an RA therapeutic that can decrease inflammation, increase resolution of 
inflammation, regenerate joints and decrease pain. 
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Table 1: Rheumatoid Arthritis Therapies 
Drug Characteristics Mechanisms of RA 
Major Side 
Effects 
Class 
OTC 
/Rx 
Name 
Anti-
inflammatory 
Analgesia 
Bone 
regrowth 
A
n
a
lg
es
ic
 
OTC Acetaminophen No Yes No 
Liver tox., 
Multiple drug 
interactions 
Rx Narcotics No Yes No 
Risk of 
dependence 
N
S
A
ID
s 
OTC Aspirin Yes Yes No 
GI irritation, 
Reyes’ syndrome, 
kidney tox. 
OTC 
Ibuprofen, 
Aleve® 
Yes Yes No 
GI irritation, liver 
or kidney tox. 
Rx 
Vioxx®, 
Celebrex® 
Yes Yes No 
Cardiovascular 
risk, liver or 
kidney tox. 
S
te
ro
id
 
Rx Prednisone Yes Yes 
Thins 
bones 
Weight gain, 
cataracts, diabetes 
D
M
A
R
D
 
Rx Methotrexate Yes Yes 
Slows 
Joint 
Damage 
Increased risk of 
infections, 
nausea, low blood 
count 
Rx TNF- blockers Yes Yes No 
ADA, increased 
risk of infections, 
TB, low blood 
count 
Rx Rituximab® Yes Yes 
Slows 
joint 
damage 
Increased risk of 
infections, 
nausea, low blood 
count 
Rx Kineret ® Yes Yes No 
Malignancy, TB, 
increased risk of 
infections, low 
blood count 
Rx Actemra® Yes Yes No 
increased risk of 
infections, GI 
risk,  low blood 
count, cancer 
Rx Xeljanz® Yes Yes No 
Increased risk of 
infections, 
cancer, and 
leukemia.  
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R
v
E
1
 
Rx 
Putative 
RvE1-based 
Therapeutic 
Yes Yes Yes Unknown 
  
   OTC = over the counter medication, Rx = prescription medication  
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Table 2: Lipid mediators and their anti-inflammatory and pro-resolution  
actions in inflammatory animal models. 
 
Mediators Species/disease model Action(s) 
Lipoxin 
A4/ATL 
Rabbit/Periodontitis Reduce neutrophil infiltration; prevent 
connective tissue and bone loss 
Mouse/Peritonitis stops neutrophil recruitment and lymphatic 
removal of phagocytes 
Mouse/Dorsal air 
pouch 
stops neutrophil recruitment 
Mouse/Derma l 
inflammation 
stops neutrophil recruitment and vascular 
leakage 
Mouse/Colitis Attenuate pro-inflammatory gene expression 
and reduce severity of colitis. Inhibit weight 
loss, inflammation and immune dysfunction 
Mouse/Asthma Inhibit airway hyper-responsiveness and 
pulmonary inflammation 
Mouse/Cystic fibrosis Decrease neutrophil inflammation, pulmonary 
bacterial burden and disease severity 
Mouse/Ischemia- Attenuate hind-limb I/R-induced lung injury 
reperfusion Detachment of adherent leukocytes in 
mesenteric I/R 
Mouse/Cornea Accelerate cornea re-epithelialization, limit 
sequela of thermal injury and promote host 
defense 
Mouse/Angiogenesis Reduce angiogenic phenotype: endothelial cell 
proliferation and migration 
Mouse/Bone-marrow 
transplant (BMT) 
Protect against BMT-induced graft-versus-host 
diseases 
Murine/Glomeruloneph
ritis 
Reduce leukocyte rolling and adherence 
Decrease neutrophil recruitment 
Rat/Hyperalgesia Prolong paw withdraw latency, reducing 
hyperalgesic index Reduce paw edema 
Rat/Pleuritis Shorten the duration of pleural exudation 
Resolvin 
E1 
Rabbit/Periodontitis Reduces neutrophil infiltration; prevents 
connective tissue and bone loss; promotes 
healing of diseased tissues; regeneration of lost 
soft tissue and bone 
Mouse/Peritonitis Stops neutrophil recruitment; regulates 
chemokine/cytokine production 
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Promotes lymphatic removal of phagocytes 
Mouse/Dorsal air 
pouch 
Stops neutrophil recruitment 
Mouse/Retinopathy Protects against neovascularization 
Mouse/Colitis Decreases neutrophil recruitment and pro-
inflammatory gene expression; improves 
survival; reduces weight loss 
Resolvin 
D1 
Mouse/Peritonitis Stops neutrophil recruitment 
Mouse/Dorsal skin air 
pouch 
Stops neutrophil recruitment 
Mouse/Kidney 
ischemia-reperfusion 
Protects from ischemia-reperfusion-induced 
kidney damage and loss of function; regulates 
macrophages 
Mouse/Retinopathy Protects against neovascularization 
Protectin 
D1 
Mouse/Peritonitis Inhibit neutrophil recruitment 
Regulate chemokine/cytokine production 
Promote lymphatic removal of phagocytes 
Regulate T-cell migration 
Mouse/Asthma Protect from lung damage, airway 
inflammation and airway hyper responsiveness 
Human/Asthma Protectin D1 is generated in humans and 
appears to be diminished in asthmatics 
Mouse/Kidney 
ischemia-reperfusion 
Protect from ischemia-reperfusion-induced 
kidney damage and loss of function; regulate 
macrophages 
Mouse/Retinopathy Protect against neovascularization 
Rat/Ischemic stroke Stop leukocyte infiltration, inhibit NF-κB and 
cyclooxygenase-2 induction 
Human/Alzheimer's 
disease 
Diminished protectin D1 production in human 
Alzheimer's disease 
 
Adapted from Table 2 of Serhan CN, et al. 2008 
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Table 3: Resolvins and their anti-nociceptive and anti-inflammatory 
actions in animal models of pain. 
 
Resolvin Animal Pain model 
Anti-nociceptive and  
anti-inflammatory action 
RvE1 Mouse Formalin Reduce inflammatory pain 
CRG Decrease inflammatory pain 
Reduce IL-1β, IL-6, TNF-α, and CCL2 
expression 
Reduce edema and neutrophil infiltration 
CFA Reduce inflammatory pain 
CAP Reduce spontaneous pain 
TNF-α Abolishes heat hyperalgesia and 
mechanical allodynia 
Incision Reduce postoperative pain 
RvD1 Mouse CRG Reduce inflammatory pain 
CFA Reduce inflammatory pain 
Formalin Reduce inflammatory pain 
Mustard oil Reduce spontaneous pain 
PGE2 Reduce inflammatory pain 
Rat Incision Reduce postoperative pain 
SMIR Reduce postoperative pain 
AT-
RvD1 
Rat CFA Reduce inflammatory pain 
Reduce TNF-α, IL-1β, COX-2, and NF-κB 
expression 
 
Adapted from Table 2 of Ji RR, et al. 2012
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Table 4: Step-wise cleavage of prochemerin 
 
Protease C-terminal sequence 
Amino 
Acid Order Activity 
Prochemerin …YFPGQFAFSKALPRS 21-163 Inactive  
Tryptase …YFPGQFAFSK 21-158 Chemotaxis 
Plasmin …YFPGQFAFSK 21-158 Chemotaxis  
Plasmin/CPB …YFPGQFAFS 21-157 Chemotaxis, strong  
Plasmin/CPN …YFPGQFAFS 21-157 Chemotaxis, strong  
Staphopain B …YFPGQFAFS 21-157 Chemotaxis, strong  
Elastase …YFPGQFAFS 21-157 Chemotaxis 
Cathepsin G …YFPGQFAF 21-156 Chemotaxis 
PR3 …YFPGQFA 21-155 Less chemotaxis 
Chymasin …YFPGQF 21-154 No chemotaxis 
Cathepsin S …FLPGQFA 23-154 Anti-inflammatory 
Calpains …FLPGQFA 23-154 Anti-inflammatory 
 
 
Step-wise cleavage of pro-chemerin results in altered biological activity. 
 
Adapted from Table 1 from Du XY and Leung LL. 2009. 
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Table 5: Frequency of cells that stain positive for cytokine and immune cell surface 
markers by immunohistochemistry through CIA disease course. 
 
 
  
Days post onset 
Day 0  Day 2-3 Day 11-12 Day 23-25 
TNF- 0  +++ +++ ++ 
IL-6 0 ++ +++ ++ 
IFN- 0 + + 0 
CD4 0 + ++ + 
I-A
q
 (+) ++ ++ + 
Mac-1  +++ +++ ++++ +++ 
 
 
Frequency of cells in arthritic and non-arthritic limbs recognized immunohistochemistry 
by antibodies for cytokine or cell surface marker shown. 
 
*0 = 0%, (+) <1%, + = 1-10%, ++ = 10-25%, +++  =25-50%,  +++ = 50-75% 
 
Adapted from Table 1 of Müssener A, et al. 1997. 
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FIGURE 1:  Mechanisms of Rheumatoid Arthritis: Inflammation 
Macrophages participate in pro-inflammatory cytokine (TNF-, IL-6, IL-1) production 
in both (A.) T-cell driven and (B.) B-cell driven phases of RA progression. 
 
Figure 2 from Choy E. 2012  
A. 
B. 
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Figure 2: Mechanisms of Rheumatoid Arthritis: Bone Damage 
 
Schematic view of (left) a normal joint and (right) a joint affected by RA. 
 
Figure 1 from Choy E. 2012. 
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FIGURE 3: Biosynthetic Cascade, Actions and Receptors for Lipid Mediators.  
Biosynthetic cascades of selected lipid mediators derived from arachadonic acid (AA), 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). COX-2 
(cyclooxygenase-2), 5-LO (arachidonate 5-lipoxygenase), 12/15-LO (12/15-
lipoxygenase), COX-2/aspirin (COX-2 in the presence of aspirin), P450 (cytochrome 
P450), 15-LO (15-lipoxygenase) catalytically convert these precursors into 15S-
hydroxyeicosatetraenoic acid (15S-HETE), 15R-hydroxy-eicosatetraenoic acid (15R-
HETE), 18R-hydroxyeicosapentaenoic acid (18R-HEPE), 5S-hydroperoxy-18R-
hydroxyeicosapentaenoic acid (5Hp-18R-HEPE), 17S-hydroperoxy docosahexaenoic 
acid (17S-HpDHA), 17S-hydroxydocosahexaenoic acid (17S-HDHA), 14S-
hydroperoxydocosahexaenoic acid (14S-HpDHA), as well as PG (prostaglandins), 
including PGH2, PGD2, and PGE2, and LT (leukotrienes), including LTA4, LTC4 and 
LTB4) participate in chronic inflammation if acute inflammation fails to resolve. 
Resolvins including RvE1, RvE2, RvD1 and RvD2, along with LipoxinA4 (LXA4), 
aspirin triggered LX4 (AT-LXA4), Protectin D1 (PD1), and Maresin 1 (MaR1) promote 
resolution of inflammation by binding to cell surface receptors such as  lipoxin A4 
receptor/formyl peptide receptor 2 (ALX/FPR2), cysteinyl leukotriene receptor 1 
(CysLT1), G-coupled receptor 32 (GPR32), LTB4 receptor 1 (BLT1), Chemokine-like 
Receptor 1 (CMLKR1, also called ChemR23) and other unidentified  receptors. 
 
Figure 2 from Serhan CN and Petasis NA. 2011.   
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Figure 4: RvE1 inhibits TNF--induced NF-kB activation in ChemR23-transfected 
HEK cells. 
 
Dose-dependent RvE1 inhibition of TNF--induced NF-B activation with an EC50 of 
1.0 nM in ChemR23-transfected (filled circles) but not in mock-transfected (open circles) 
NF-B-luciferase reporter HEK cell.  
 
Adapted from Figure 3D of Arita M, et al. 2005. 
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Figure 5. Comparison of prochemerin across species. 
 
Domains of signal peptide, chemotaxis, and anti-inflammation are indicated.  
 
Figure 1 from Du XY and Leung LL. 2009.  
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A. 
B.  
 
 
Figure 6: Proteolytic processing of prochemerin results in altered biological activity  
 
Calcium release induced by prochemerin, chemerin, and peptides derived from their C 
terminus on ChemR23 transfected cells. (A.) The biological activity of recombinant 
prochemerin (○), recombinant processed chemerin (•), the 25-amino acid C-terminal 
peptide of prochemerin (prochemerin 
139–163, □), and the corresponding 19-amino acid C-
terminal peptide of processed chemerin (chemerin 
139–157
, ▪), using the aquaporin-based 
intracellular Ca2+ release assay. (B.) Effects of N-terminal modifications of chemerin-
derived peptides chemerin 
139–157
 (▪) and N-terminally truncated peptides: chemerin 151–
157
 (▵), chemerin 150–157 (▾), chemerin 149–157 (•), chemerin 148–157 (○), and chemerin 146–157 
(□). The curves represent the mean ± S.E. of duplicate data points and are representative 
of at least three independent experiments. 
 
Adapted Figures 1 and 3A from Wittamer V, et al. 2004.   
. 
. 
66 
 
 
 
 
 
Figure 7: RvE1 pretreatment reduced inflammatory neutrophils and inflammatory 
IL-1 in BALF of OVA-treated mice 
 
(A.) Percentage of neutrophils in bronchoalveolar lavage fluid (BALF) as an indicator of 
numbers of neutrophils in lung tissues. Significant differences compared to naïve ***P< 
0.001. (B.) Concentrations of the pro-inflammatory cytokines IL-1b in BAL fluid after 
induction of an OVA-induced experimental acute inflammatory lung exacerbation. Data 
are mean ± SEM (n=7). Significant differences compared to naïve # # P< 0.01, compared 
to the peak *P< 0.05, **P< 0.01 and ***P< 0.001. 
 
Adapted from Figure 2A and 3C of Flesher RP, et al. 2013. 
A. 
B. 
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Figure 8: RvE1 reduces pro-inflammatory mediators in TNBS-induced colitis.  
 
Quantitative real-time PCR analysis of mRNA expression of inflammatory mediators in 
colons obtained on day 4 from control mice (white column), mice treated with TNBS 
alone (black column), or mice receiving TNBS plus pre-treatment with RvE1 (gray 
column). * P <0.01 (n=6). 
 
Figure 4C, Arita M, et al. 2005. 
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Figure 9.  RvE1 enhances bacterial clearance in E. coli-induced pneumonia mouse 
model. 
 
(A.) Mice treated as follows: t=0:  saline, EPA, or RvE1 i.v.; t=30min: intratracheal left 
lung instillation of HCl or PBS; t=12 hrs: left lung inoculation with ~10
6
 CFU of E. coli; 
t= 24 hrs: the left lungs collection, homogenization, and a BGI calculation. *, p<0.05 for 
saline/HCl/E. coli vs saline/PBS/E. coli; **, p<0.005 for RvE1/HCl/E. coli vs 
saline/HCl/E. coli. Mean +/- SEM (n =12). (B.) RvE1 does not directly impair the growth 
of E. coli in vitro. E. coli was plated on blood-agar with 0, 0.1, 1, 10, 100 nM RvE1, 
incubated for 24h at 37°C, and colonies were counted. Mean+/-SEM (n = 3). 
 
Adapted from Figure 2 and 3 from Seki H, et al. 2010. 
A. 
B. 
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Figure 10.  RvE1 is anti-hyperalgesic at doses 1000-fold lower than EPA in the acute 
CFA-evoked heat hyperalgesia model 
 
Acute actions of RvE1, RvD1, DHA and EPA compared with 1% ethanol (Vehicle) in the 
CFA-evoked heat hyperalgesia model. #P<0.05, (n=4-7). For the CFA model, thermal 
paw withdrawal latency (PWL) and data were presented normalized for each animal as 
the maximum possible effect of hyperalgesia (M.P.E.) (%) in terms of the change in the 
PWL ipsilateral to CFA. These values were calculated as follows: M.P.E.(%) = (TimeX 
PWL−Time0 PWL)/(baseline − Time0 PWL ). Time0 is the PWL 24 hrs. following CFA, 
before drug ministration.  
 
From Figure 2B, Xu ZZ, et al. 2010.  
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Figure 11.  RvE1 reduces of carrageenan (CRG)-elicited heat hyperalgesia, even as 
inflammatory responses remain increased.  
 
(A.) Paw withdrawal latency (PWL), (B.) paw edema, (C.) neutrophil infiltration, and 
(D.) expression of pro-inflammatory cytokines and chemokines in the inflamed paw, 
following intraplantar pretreatment of resolvins. Edema, neutrophil infiltration, and 
cytokine expression at protein levels were examined by paw volume (B.), 
myeloperoxidase (MPO) activity (C.), and cytokine array (D.), respectively, at 4 or 2 
hours after CRG injection. *P<0.05, vs. vehicle (A., B.) or naïve (C., D.), #P<0.05, vs. 
CRG, n=3–6. 
 
Adapted from Figure 2E-H, Xu ZZ, et al. 2010.  
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Figure 12.  RvE1 pretreatment reduces formalin induced phase 2, but not phase 1 
pain response. 
 
(A.) Preemptive i.t. RvE1 reduced second phase formalin-induced pain. (B.) Dose 
response curve of % inhibition of formalin-induced second phase pain (vs. vehicle) of 
pre-emptive i.t. RvE1, morphine and NS-398, a selective COX-2 antagonist (n=5-8 
mice). 
 
Figures 1B-C from Xu ZZ, et al. 2010. 
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Figure 13. TNF-α enhances excitatory synaptic transmission, sEPSC in spinal 
lamina II neurons via both TNFR1 and TNFR2.  
 
(A.) Patch-clamp recording in spinal cord slices shows an increase in the frequency of 
sEPSC after bath application of TNF-α (10 ng/ml, 2 min). (Aa.) and (Ab.) are enlarged 
recordings before and after TNF-α treatment, respectively. (B.) TNF-α increases the 
frequency of sEPSC in WT mice. This frequency increase is abolished in TNFR1-KO and 
TNFR1/2 -DKO mice and partially reduced in TNFR2-KO mice. *P<0.05, compared to 
pretreatment baseline; 
#
P<0.05, compared to WT. The number of recorded neurons is 
indicated inside each column. (C.) TNF-α fails to increases the amplitude of sEPSC in 
WT mice, in TNFR1-KO and TNFR2-KO mice, as well as in TNFR1/2-DKO mice. All 
the data are expressed as the ratio of corresponding baseline. The number of recorded 
neurons is indicated inside each column. 
 
Figure 4 from Zhang L, et al. 2011. 
  
A. B. 
C. 
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Figure 14.  RvE1 inhibits TRPV1, but not TPRA1 currents on DRG cells. 
 
(A.) RvE1 inhibits the capsaicin-induced inward TRPV1 current on a DRG cell. (B.) 
RvE1 does not inhibit the AITC-induced inward TRPA1 current on a DRG cell. (C.) 
RvE1 inhibits capsaicin-induced inward current on DRG cells with an IC50 of 0.4 +/- 
0.05 ng/ml (n=5-8 neurons).   
 
Adapted from Figure 1B, C, F of Park C-K, et al. 2013.  
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Figure 15: ChemerinR23 co-localizes with TRPV1 on cultured neurons and with 
NeuN on the superficial dorsal horn. 
 
Co-localization of ChemR23 (A.) with TRPV1 in cultured DRG neuron and (B.) with 
NeuN, a neuron-specific marker, in the superficial dorsal horn.  Scale bars, 25 μm. All 
data are means +/- SEM.  *P < 0.05. (n=5-8 mice). 
 
Figures 1G from Xu ZZ, et al. 2010 
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Figure 16: RvE1 significantly enhances bone healing in vivo.  
 
(A.) 1 mm wide circular bone defect was created in the parietal bone of WT and 
ChemR23 Tg  mice and treated with subperiosteal injections of RvE1 (100ng in 20 µL) 
every other day for 2 weeks. Bone healing is expressed as percentage of original defect. 
RvE1 significantly enhanced bone healing in both WT and ChemR23Tg (Tg) mice (Mean 
+ SEM, P<0.05, t-test, n=16 for each group). No significant difference between WT and 
Tg was found. (B.) Histological section across a healing calvarial bone defect (Masson’s 
trichrome staining). 
 
From Figure 4 of Gao L, et al. 2013 
  
A. B. 
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Figure 17:  RANKL and OPG measurements in primary osteoblast cultures.  
 
IL-6 and IL-6 receptor (IL-6/ILR) treatment of primary osteoblast induces an 
inflammatory phenotype. 48 hrs. culture supernatants were assayed for RANKL and OPG 
by ELISA. (A.) RANKL expression was not significantly altered by RvE1. (B.) 
However, OPG expression was rescued in an RvE1 dose-dependent manner, while EPA 
and chemerin was not. All experiments show mean +/- SEM.  *P<0.05 ANOVA. (n=4) 
 
From Figure 6 of Gao L, et al. 2013. 
  
77 
 
 
 
 
 
 
 
 
 
Figure 18:  RvE1 induces restoration of lost bone in P. gingivalis-induced ligature 
model of periodontitis in rabbits.  
 
Radiographic bone loss was quantified. Baseline periodontal disease (6 wks.) resulted in 
30% bone loss (inset). Radiographic analyses revealed that RvE1 restored the lost bone 
(95%), whereas the vehicle alone, LTB4-, and PGE2-treated groups showed 13, 9, and 
18% more bone loss, respectively. 
 
Figure 3 from Hasturk H, et al. 2007. 
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Figure 19: Total organic synthesis of RvE1.  
 
Precursors 1–3 were prepared in isomerically pure form from starting materials with 
known stereochemistry and coupled sequentially to form acetylenic intermediate 
compound 4, which was selectively hydrogenated to form isomerically pure RvE1.  
 
From Figure 2A of Arita M, et al. 2005  
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FIGURE 20: The Proposed RvE1 Metabolome. 
Human and murine tissues convert RvE1 to the illustrated products. The asterisk (∗) 
denotes identified proposed intermediates. The stereochemistry of the alcohol at carbon-
12 position in the 10,11-dihydro-RvE1 metabolite remains to be determined. 
 
Figure 4 from Hong S et al, 2008 
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Figure 21. RX-10001, a synthetic RvE1, rescues corneal integrity in the 
scopolamine-induced model of dry eye. 
 
Corneal permeability measured as the uptake of Oregon Green Dye (OGD) in untreated 
and experimental dry eye controls (EDE 5D) and the 2 treatment groups: RX Vh 
(polysorbate vehicle) and RX 01 (synthetic RvE1; RX-10001). Bars indicate mean group 
changes in OGD in response to treatment with RX Vh or RX 01  and are expressed as 
percent staining increase with the difference in staining at 5 days of RX Vh compared 
with normal untreated controls normalized to 100%. # P< 0.005 (n=18–20). 
 
Adapted from Figure 1 of  de Paiva CS, et al. 2012. 
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Figure 22. Time course of RvE1 conversion to 18-oxo-RvE1 via human 15-PGDH 
and NAD+. 
 
RvE1 is converted to a biologically inactive 18-oxo-RvE1 via dehydrogenation via 
recombinant human 15-PGDH and NAD+. NADH formation was monitored by 
absorbance at 340 nM.  Closed circles: in the presence of 15-PGDH, open diamonds: in 
the absence of 15-PGDH. 
 
From Figure 3 of Arita M, et al. 2006. 
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